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Abstract  
Small Cell Lung Cancer (SCLC) accounts for 15-20% of all lung cancers and 
kills at least one person every 2 hours in the UK.  There is no effective 
treatment and overall 2-year survival is less than 5%. Patients with SCLC have 
poorly understood local and systemic immune defects. Previous studies have 
shown several important defects in cell-mediated immune responses in patients 
with SCLC. A better understanding of interactions between SCLC tumour cells 
and immune cells may lead to the development of novel therapeutic 
approaches. There is increasing recognition that immunological biomarkers may 
add to traditional histological analyses and can be exploited in the management 
of multiple epithelial malignancies. There are currently no such markers used in 
the management of SCLC.  
 
In my PhD project, I have shown that cell lines from different SCLC patients 
have differential immunosuppressive capabilities. These properties are 
mediated by the secretion of differing levels of soluble molecules that can 
suppress the mixed leukocyte reaction (MLR) and CD4+ T cell proliferation, 
induce IL-10 secretion and differentiation of functional 
CD4+CD25+CD127+FoxP3+Helios- regulatory T cells (Tregs) from naïve CD4+ T 
cells. IL-15 is secreted by SCLC cells in culture in proportion to their 
immunosuppressive capability. Its in vivo relevance is supported by its  
presence in tumour biopsy samples. The suppressive effect on CD4+ T cell 
proliferation and the induction of Treg cell population was not affected by 
blocking IL-10 or TGF-β signalling but was partially reversed by blocking IL-15 
activity. Therefore, IL-15 is one, though not the only, soluble molecule produced 
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by SCLC cells to mediate immune suppression by inducing increased 
population of Treg cells. This may represent a mechanism by which SCLC cells 
can suppress the immune response.  
 
In addition, SCLC cells supressed TNF-α release from monocytes in response 
to LPS stimulation, down-regulated expression of CD16 and CD86 and up-
regulated expression of CD163 and CD206 on monocyte-derived macrophages 
(MDMs) upon activation. This M2-like phenotype poralization was associated 
with decreased TNF-α and IL-6 production and increased IL-10 secretion. 
These effects were abrogated by blocking the signalling of bombesin-like 
peptides (BLPs) that are neuropeptides produced by SCLC cells using a GRP 
receptor (GRP-R) antagonist. Therefore, the polarization of macrophages to an 
M2-like phenotype by SCLC cell-derived BLPs may represent another 
mechanism by which SCLC tumours suppress the immune response.   
Finally, SCLC tumour biopsies were shown to be infiltrated with various 
mononuclear immune cells and Treg cells.  CD45 and FoxP3 were used as pan-
inflammatory cell and Treg cell markers respectively. An elevated CD45+ 
infiltrate was predictive of prolonged survival in SCLC independent of age, sex, 
stage or treatment strategy. An elevated FoxP3+/CD45+ ratio was predictive of a 
significantly worse prognosis.  
 
This study identifies potential mechanisms by which SCLC tumour cells may 
downregulate local and systemic immune response, and also identifies an 
independent prognostic marker to predict patient survival in SCLC. Further, IL-
15 and BLPs are potential novel therapeutic targets in SCLC. 
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1.1 Lung Cancer  
 
Lung cancer, a highly invasive, rapidly metastasizing and prevalent cancer, is 
the leading cause of cancer death in the UK and worldwide (1,2).  It is broadly 
categorised into two forms of lung cancer according to the shapes of cells and 
clinical behaviour: non-small cell lung cancer (NSCLC) (about 85% of all lung 
cancer) and small cell lung cancer (SCLC) (about 15%) (1,3).  
 
NSCLC can be further divided into three types. Adenocarcinoma accounts for 
40% of lung cancer that occurs mainly in current or former smokers but is also 
the most common lung tumour seen in non-smokers. It arises in the epithelial 
cells of segmental bronchi and alveoli (1). Adenocarcinoma tumours grow 
slower than other types of lung cancer and are often found before metastasis 
(3). Squamous cell carcinoma is the second most common type of lung cancer 
(30-35%) and is closely correlated with a history of cigarette smoking (1).  The 
tumour cells are derived from the epithelial cells of main and lobar bronchi, and 
usually located in within the lung (3). Large cell carcinoma (10%) derives from 
the hormonal cells of the lung cells (1). It tends to grow and spread quickly and 
therefore the prognosis and survival rate remain poor (4-6). Currently most 
patients with NSCLC are diagnosed at an advanced stage and have a poor 
prognosis (7). Despite advances in early detection and standard treatments 
including curative surgery or radiotherapy possibly in combination with 
chemotherapy, patient survival remains low. The mortality rate is much higher 
than other types of cancer and the predicted 5-year survival rate is 15.9% after 
diagnosis (7,8).  
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Small cell lung cancer (SCLC) is a highly malignant cancer (3). SCLC cells are 
composed of smaller than normal, undifferentiated, round oval or spindle-
shaped cells. It often originates in proximal bronchi near the centre of the chest 
and it is characterised by rapid growth and early metastatic spread (9). SCLC 
has the most aggressive clinical course of any type of pulmonary tumour and 
thus surgical resection is rarely possible (10). SCLC is more responsive to 
chemotherapy and radiotherapy, however, SCLC has often widely disseminated 
by the time of diagnosis.  The mortality from diagnosis is therefore greater than 
other types of lung cancer with median survival of 2-4 months. 2-year survival is 
less than 5% and 5-year survival is 5-10% for SCLC, despite treatment (10 -12).  
 
Cigarette smoking is the greatest single risk factor for developing lung cancer 
(13). Other drivers of the lung cancer epidemic include radon exposure, 
atmospheric pollution, industrial exposure to carcinogens and chronic lung 
disease (13,14). It has been shown that SCLC displays a stronger relation with 
tobacco smoking than NSCLC, and over 95% of SCLC cases are attributable to 
cigarette smoking (15,16).   
 
 
1.2  Clinical features, Diagnosis and Staging of SCLC.  
 
Typically, SCLC grows silently and metastasizes to mediastinal lymph nodes 
early. Most patients with SCLC present with a short duration of symptoms, 
usually 8-12 weeks before presentation but have widespread disease at 
diagnosis (17). Symptoms can result from local tumour growth, intrathoracic 
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spread, distant spread, and/or paraneoplastic syndromes. These may include 
chest pain, cough, shortness of breath and hemoptysis. Moreover, the 
symptoms including headache, blurred vision, photophobia, nausea and 
vomiting are common (18). In addition to direct effects, SCLC is associated with 
paraneoplastic syndromes (19).  These are triggered by an altered immune 
system response to a neoplasm or ectopic production of a hormone or cytokine, 
affecting the endocrine and neurologic systems in patients (19).  
 
To assess SCLC at presentation and to guide its management, smoking history, 
blood tests, imaging (chest X-ray, CT, MRI and PET scan) are used, together 
with cellular phenotyping (sputum cytology and tissue biopsy analysis) (20,21). 
In some cases, it is difficult to differentiate from NSCLC based on morphology 
alone, therefore immunohistochemistry is also used in diagnosing SCLC (21).  
 
Since SCLC is extremely chemo- and radiosensitive, systemic chemotherapy is 
presently the cornerstone of treatment of SCLC. The clinical purpose of staging 
is to decide whether thoracic radiation should be incorporated in combination 
with chemotherapy for localized disease. TNM (T: primary tumour, N: regional 
lymph nodes, M: distant metastasis) staging system is commonly used to stage 
NSCLC and most cancers (22). However, the clinical behaviours of NSCLC and 
SCLC are different and are treated in very different ways. The LD (limited stage 
disease) versus ED (extensive stage disease) classification system defined by 
the Veterans Administration Lung Study Group is widely utilized in SCLC 
because of its simplicity and clinical utility (23,24). LD is SCLC that is confined 
to one hemithorax including ipsilateral supraclavicular lymph nodes and can be 
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encompassed within a single radiation port. ED includes any cases of SCLC that 
have spread to the opposite lung and/or to distant sites in the body (23).  
 
1.3  Treatment of SCLC.  
 
Since SCLC is typically disseminated or at least locally advanced and 60-70% 
patients have ED at the time of diagnosis, the possibility of surgical resection 
immediately is unlikely (25). However, SCLC cells are extremely sensitive to 
chemotherapeutic drugs in the primary treatment modality (26). Therefore, the 
typically treatment of SCLC is chemotherapy with or without radiation. However, 
despite initial objective response rates, tumour relapses are common and most 
patients eventually succumb to the disease (27).  
 
1.3.1 Chemotherapy  
The discovery of chemotherapy as a treatment for SCLC has significantly 
improved patient survival. The commonly used combination chemotherapeutic 
agents to treat SCLC include cyclophosphamide (C), doxorubicin (A), and 
vincristine (V), (CAV); cyclophosphamide (C), doxorubicin (A), and etoposide 
(E), (CAE); and cisplatin (P) and etoposide (E), (PE) (28). Novel agents with 
significant single-agent activity in SCLC, include paclitaxel, docetaxel, 
vinorelbine, irinotecan and topotecan and gemcitabine (28). The standard 
chemotherapy for the first-line treatment of SCLC is 4-6 cycles of PE (29,30). 
The combination of carboplatin and etoposide has been shown to have similar 
effect as PE in both LD and ED patients, the median survival is approximately 
12 months (31). A number of studies have also demonstrated significant survival 
	   23	  
advantage with the irinotecan-cisplatin regime compared with PE in the patients 
with ED. Median survival has been reported to have improved from 9.4 months 
to 12.8 months, and 2-year-survival from 5.2% to 19.5% (32-35). Notably, 
however, a further phase III trial in America has failed to confirm this result (36).  
This may be because the response duration is often short (approximately 9 
months), the tumour becomes resistant to the chemotherapy (37).  Following 
tumour relapse, second-line chemotherapy is much less effective than initial 
treatment (38). A number of studies have attempted to address this by 
intensifying chemotherapy dose, using new combinations of chemotherapeutic 
agents and trailing new drugs to prolong patient survival (10).  
 
1.3.2 Radiotherapy  
In addition to cytotoxic therapy, SCLC cells are more sensitive to radiotherapy 
than NSCLC (39). Meta-analyses have shown that the addition of thoracic 
radiation therapy to chemotherapy moderately improves the survival in patients 
with LD SCLC (40, 41). A dose of 45 Gray (Gy) of concurrent thoracic 
radiotherapy is considered as standard therapy. Earlier (less than 30 days) 
chest radiotherapy with platinum-based chemotherapy improved 2- and 5-year 
survival in LD SCLC patients (42). Furthermore, patients given twice daily 
irradiation showed significantly improved survival rates in LD SCLC (43). 
 
1.4  Pathogenesis of SCLC.  
 
The pathogenesis of SCLC is like other cancers, beginning with carcinogen-
induced initiation events, followed by a long period of promotion and progression 
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in a multistep process. The process involves malignant transformation, 
uncontrolled cellular proliferation, avoidance of apoptosis, angiogenesis, 
migration and invasion of distant tissues.  
 
1.4.1 Carcinogenesis  
SCLC, similar to other lung cancers, is the end stage of multiple-step 
carcinogenesis, driven by genetic and epigenetic damage caused by chronic 
exposure to tobacco smoke carcinogens. More than 20 carcinogens contained 
in tobacco smoke are strongly associated with development of lung cancer (44). 
These include polycyclic hydrocarbons, nitrosamines and aromatic amines. 
Chronic exposure to such agents induces DNA damage, misreplication and 
mutation and so smokers are predisposed to developing lung cancer (45, 46). 
The specific sequence of genetic instability in SCLC remains unclear. However 
it has been shown to exist at two levels. Large-scale chromosomal instability 
refers to losses or gains of whole or large portions of chromosomes. Loss of 
heterozygosity (LOH) refers to loss of normal, functional alleles at a 
heterozygous locus. It may arise from several mechanisms (47). LOH on 
chromosome 3p affecting multiple genes is one of the most frequent and earliest 
genetic alterations in SCLC pathogenesis and is observed in more than 90% of 
SCLC (48). These affected regions contain a variety of tumour suppressor 
genes such as fragile histidine triad (FHIT) and von Hippel Lindau (VHL), and 
may therefore contribute to the development of SCLC (49,50). Other common 
chromosomal alterations include loss of 5q, 17p and 13q, which are loci with 
tumour suppressor genes including p53 and Rb (51).  In addition, comparative 
genomic hybridization analyses have revealed that a large number of SCLCs 
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harbor gains of 1p, 2p, 3q, 5p, 8q and 19p. These regions encode well-known 
proto-oncogenes, such as MYC and KRAS (52). Microsatellite instability (MSI) 
refers to small deletions or expansions in the length of repetitive DNA 
microsatellites, which consists of long, tandem repeats of between one and six 
nucleotides (53). Replication error (RER) leading to MSI has been implicated in 
the pathogenesis of tumour (53).  RER derived from deficiency or mutations in 
DNA mismatch repair (MMR) genes has been found in approximately 35% of 
SCLC (54).   
 
1.4.2 Dysregulated Cellular Proliferation  
A variety of peptide growth factors and their receptors are secreted and 
expressed by SCLC cells and adjacent normal cells (55). It leads to the 
development of several autocrine (secreted by and act on the same cell) and 
paracrine (secreted by one cell and act on another) growth stimulatory loops 
(55). The best-characterized autocrine system in SCLC includes three 
bombesin-like peptides (BLPs) and their receptors. Bombesin is a 14-amino-
acid neuropeptide (56), Gastrin-releasing peptide (GRP) is a 27-amino-acid 
mammalian homologue of bombesin, Neuromedin B (NMB), a 10-amino-acid 
peptide, is the third member of BLP family (56). Bombesin and GRP share a 
conserved bioactive C-terminal sequence so that both peptides have the same 
physiological effects (57). They signal through G protein-coupled BLP receptors: 
GRP receptor (GRP-R), NMB receptor (NMB-R), and bombesin receptor 
subtype 3 (BB3) (56, 58). GRP-R has high affinity for bombesin and GRP and 
very low affinity for NMB (58). Through the binding of GRP-R, multiple cellular 
signal transduction pathways are activated (Fig. 1.1), including tyrosine 
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phosphorylation of focal adhesion kinase (FAK) and activation of protein kinase 
A (PKA), protein kinase C (PKC), mitogen-activated protein kinases (MAPKs) 
and phosphatidylinositol 3-kinases (PI3Ks) (59). These activated signaling 
pathways mediate cell proliferation, survival and migration during umour 
progression.   
 
Figure 1.1: Signaling pathways associated with GRP-R in cancer. The GRP-R is a G protein-
coupled receptor, after agonist binding, the receptor expose intracellular sites involved in the 
interaction with G-protein heterotrimer, which contains α, β and γ subunits. GRP-R interacts with 
Gαq and Gα12/13 subfamilies. Gαq activation triggers phospholipase C (PLC)-mediated 
generation of the second messengers, which induce rapid release of Ca2+ and diacylglycerol 
(DAG) that activate protein kinase C (PKC). The activation of PKC, in turn, activates mitogen-
activated protein kinase (MAPK) pathways. Ca2+ release can also induce adenylyl cyclase (AC) 
and cyclic adenosine monophosphate (cAMP), leading to activation of protein kinase A (PKA). In 
addition, Gα12/13 subunit of G protein activates the Rho family of guanosine triphosphatases 
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(GTPases), which induce tyrosine phosphorylation of a set of focal adhesion kinases (FAKs). 
The phosphorylation of Src (the largest family of non-receptor protein tyrosine kinases) 
stimulated by Gα12/13 leads to downstream induction of phosphatidylinositol 3-kinase (PI3K) 
and subsequent activation of Akt and mTOR. Src can also be activated by βγ subunits, mediate 
matrix metalloproteinase (MMP) activity and release of epidermal growth factor receptor (EGFR) 
ligands. The subsequent phosphorylation of EGFR leads to activation of PKC and MAPK 
signalling pathways. These cell signalling pathways associated with GRP-R regulate tumour cell 
proliferation, survival and migration.  
 
Up to 60% of SCLC cell lines express GRP and all express NMB (60,61). The 
mechanism by which this growth stimulatory autocrine loop remains unclear. 
Mutations of either GRP/bombesin or their receptor have not been identified in 
lung cancers (62). However, GRP-R is transcriptionally up-regulated with long-
term tobacco exposure. GRP-R activation is associated with proliferative 
response of bronchial cells in vitro to the mitogenic effects of BLPs (63). 
Blocking GRP-R signaling with neutralizing antibodies against GRP/bombesin or 
receptor antagonists inhibits tumour growth in vivo and in vitro (64). The 
development of resistance to conventional chemotherapy, which is inevitable in 
SCLC, is accompanied by an increase in expression of neuropeptide growth 
factor receptors (65). These findings support a role for BLP signalling in the 
pathogenesis of SCLC.  
 
SCLC cells also display dysregulated expression of other crucial cell 
proliferation regulators. Myc (myc, N-myc and L-myc) family genes are involved 
in a wide range of cellular processes including proliferation, differentiation and 
tumourigenesis (67). Expression and amplification of these genes has been 
found in about 20% SCLC tumour samples and 50% of SCLC cell lines (66,67). 
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Moreover, increased N-Myc expression has been correlated with poor survival 
and chemotherapy response in SCLC (68). Inactivation of tumour suppressor 
p53 and Rb genes, which are also involved in the induction of apoptosis and 
control of cell cycle, occur commonly in SCLC (69).  
 
1.4.3 Avoidance of Apoptosis 
A reduced tendency to programmed cell death (apoptosis) is a crucial step in 
malignant transformation and is also important in resistance to chemo and 
radiotherapies. Over expression of the BCL-2 proto-oncogene that protects cells 
from apoptosis is common in SCLC tumours and cell lines, and may thus play a 
role in the pathogenesis of SCLC (70, 71). In addition, SCLC cells frequently 
display mutations of the p53 gene, which may cause both loss of its tumour 
suppressor functions and loss of the ability to induce apoptosis, cell cycle arrest 
and DNA repair (69, 72). Moreover, restoration of p53 function is sufficient to 
suppress the growth of SCLC cells due to induction of apoptosis (69). 
Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that regulate several 
cellular processes including proliferation, growth, apoptosis, and cytoskeletal 
rearrangement (73), and the PI3K/Akt signaling pathway delivers an anti-
apoptotic signal to promote cell survival (74). These proteins are constitutively 
active in SCLC cell lines. PI3K inhibition markedly inhibits SCLC cell 
proliferation in an anchorage-independent fashion and promotes apoptosis (75). 
In addition, in a subset of SCLC where a PI3KCA mutation is present, inhibition 
of PI3K signalling induces apoptosis and inhibits tumour growth in SCLC (76).  
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1.4.4 Angiogenesis  
Angiogenesis is crucial in neoplastic development and progression. The 
formation of new blood vessels not only supplies oxygen and nutrients, but also 
provides a means for the tumour to spread haematogenously (77). Vascular 
endothelial growth factor (VEGF) plays a critical role in angiogenesis (78). 
Serum VEGF level is significantly higher in SCLC patients and correlates with 
poor survival (79). Inhibition of the VEGF receptor blocks SCLC cell proliferation 
and angiogenesis in vivo (80), and over-expression of VEGF on tumour biopsies 
predicts poor prognosis in SCLC patients (81).  In addition, increased levels of 
basic fibroblast growth factor (bFGF), another growth factor of angiogenesis, is 
observed in serum from SCLC patients and correlates with survival (82).  
 
1.4.5 Migration and Invasion  
Whilst SCLC is often disseminated at the time of clinical presentation, the 
mechanisms by which SCLC cells invade tissue remain unclear. Many receptor 
tyrosine kinases (RTKs) are overexpressed in SCLC, notably c-Met (83). 
Stimulation of SCLC cells with hepatocyte growth factor (HGF) (the ligand for c-
Met) significantly increases formation of filopodia and migration of cellular 
clusters (84). Matrix metalloproteinases (MMPs), a family of zinc-containing 
proteolytic enzymes, facilitate tumour invasion, the establishment of metastases, 
and the promotion of tumor-related angiogenesis (85). MMPs (MMP-1, -2, -7, -9, 
-14 and -15) are widely expressed in SCLC and represent independent negative 
prognostic factors for survival (86). E2F1, a transcription factor for MMPs is 
overexpressed and represents an independent and adverse prognostic factor. 
Depletion of E2F1 inhibits SCLC cell migration and invasion (87).  SCLC has a 
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propensity for metastasis to the bone marrow (88). C-X-C chemokine receptor 
type 4 (CXCR4, CD184) acts as a receptor for chemokine (C-X-C motif) ligand 
12 (CXCL12) is highly expressed on SCLC cells (89). CXCR4 has a central role 
in haematopoetic cell migration to the bone marrow, and so CXCR4: CXCL12 
signaling may stimulate SCLC cell invasion through extracellular matrix and 
bone marrow metastasis (89).  
 
1.5  Tumour Microenvironment.  
 
The tumour microenvironment is the cellular environment in which the tumour 
exists. Stromal elements include surrounding blood and lymph vessels, 
fibroblasts of various phenotypes, extracellular matrix (ECM) and many different 
types of immune and inflammatory cells (90). The interactions between 
malignant and non-transformed cells can contribute to cancer progression, 
invasion and metastasis (90).  
 
1.5.1 Extracellular matrix (ECM) 
The ECM is a large collection of extracellular molecules secreted by resident 
cells, including proteins, glycoproteins, proteoglycans and polysaccharides with 
different physical and biochemical properties (91). The function of ECM is to 
regulate cell adhesion, migration, cell-to-cell communication and differentiation. 
Conversely, abnormal ECM contributes to cancer progression by promoting 
cellular transformation and metastasis as well as facilitating tumour-associated 
angiogenesis and inflammation (92). In SCLC, it has been shown that ECM 
proteins support SCLC cell growth in vivo (93) and SCLC tumours are 
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extensively infiltrated by ECM proteins (fibronectin, laminin and collagen IV) at 
both primary and metastatic sites (94). In addition, adhesion of SCLC cells to 
ECM in vitro enhances tumorigenicity and confers resistance to apoptosis 
induced by chemotherapeutic agents through interactions with b1 integrins 
(α2β1, α3β1, α6β1 and αvβ1) (94). 
 
1.5.2 Fibroblasts 
Fibroblasts are flat, elongated non-differentiated cells in the connective tissue. 
The functions of fibroblasts include deposition of ECM, regulation of epithelial 
differentiation, regulation of inflammation and involvement in would healing. 
(95,96). Myofibroblasts are a subpopulation of fibroblasts that are differentiated 
from residential fibroblasts in response to paracrine signals (97). Activated 
myofibroblasts expressing α-smooth-muscle actin within desmoplastic lesions 
are associated with malignant tumours and called cancer-associated fibroblasts 
(CAFs) (98). There is increasing evidence showing that CAFs are important 
promoters of tumour growth and progression (99). Various growth factors 
secreted by CAFs including HGF, fibroblast growth factor (FGF) and insulin-like 
growth factor 1 (IGF1) are mitogenic for malignant cells (90). Moreover, 
fibroblasts are an important source of MMPs and CXCL12 that can favor tumour 
growth, invasion and metastasis (99,100). In addition, SCLC cell lines secrete a 
variety of molecules that are stimulatory to fibroblasts, including GRP and 
transforming growth factor-β (TGF-β) (101, 102). GRP promotes fibroblast 
proliferation (103). TGF-β  can increase ECM production (104), induce 
epithelial–mesenchymal transition (EMT) in malignant cells and promote 
immunosuppression (105).  
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1.5.3 Immune cells and the tumour microenvironment   
In addition to fibroblasts, tumour stroma contains various cells of the immune 
system (Fig. 1.2). In SCLC, the local immune cell infiltrates have not been 
extensively studied. In other types of cancers, such infiltrates include tumour-
infiltrating lymphocytes (TILs): T cells and B cells, natural killer (NK) cells, 
natural killer T (NKT) cells, dendritic cells (DCs) and macrophages. These cells 
are capable of driving potent anti-tumour responses. However, in many cancers, 
tumour cells can induce a tumour-tolerant microenvironment by 
immunomodulatory mechanisms (90). Such effects may support cancer growth 
and spread (106,107).  
 
Figure 1.2. Immune cells within the tumour microenvironment.  CD45+ leukocytes that infiltrate 
into tumour comprise diverse subsets of immune cells: lymphocytes (CD3+ ) include T cells and 
B cells. B cells (CD20+) function to capture antigens and release antibodies. T cells include 
CD4+ helper T cells and CD8+ cytotoxic T cells. Effector CD4+ T cells play a central role in anti-
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tumour immune response and can be further divided into different subsets according to their 
functions and cytokine production (Th1, Th2, Th17). Regulatory CD4+ T cells are 
immunosuppressive, characterized by the high level of FoxP3 expression, low level of CD127 
expression and anti-inflammatory cytokine release. Dendritic cells (CD11c+) function as potent 
antigen presenting cells.  Myeloid-derived suppressor cells function to inhibit immune cell 
activation. Macrophages (CD68+) within tumour display different phenotypes and functions 
during tumour progression: Anti-tumoural M1-like phenotype with high levels of CD16 and CD86 
expression and pro-inflammatory cytokine production; Pro-tumoural M2-like phenotype with high 
levels of CD163 and CD206 expression and anti-inflammatory cytokine production.  
 
1.5.3.1 T lymphocytes 
Elevated levels of TILs are associated with better prognosis in many cancers 
(108). CD8+ cytotoxic effector T cells kill tumour cells by releasing perforin and 
granzymes to induce apoptosis, and are strongly associated with a good 
prognosis (109). CD4+ T helper 1 (Th1) cells favor cellular immune responses 
by producing the cytokines interleukin-2 (IL-2) and interferon gamma (IFN-γ), 
and by interacting with CD8+ cytotoxic T cells, NK cells and macrophages (109). 
CD4+ T helper 2 (Th2) cells act on B cells, favour humoral immunity by 
producing IL-4, IL-5 and IL-13. CD4+ T helper 17 (Th17) cells favour anti-
microbial tissue inflammation by producing IL-17A, IL-17F, IL-21 and IL-22, they 
are generally thought to promote tumour growth (109). CD4+ regulatory T (Treg) 
cells play immunosuppressive effects in a variety of immune cells, and high 
numbers of these cells in the tumour microenvironment correlate with worse 
prognosis in many cancers (110-112). In addition, γδ T cells present in the 
tumour microenvironment play cytotoxic activity against a wide range of tumour 
cells by releasing large amounts of IFN-γ and tumour necrosis factor (TNF)-α 
(113).  
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1.5.3.2 CD4+ Treg cells  
CD4+ Treg cell infiltration has been described in human NSCLC and ovarian 
cancer (114).  These cells are characterized by the expression of forkhead box 
P3 (FoxP3) and CD25 (115). Treg cells function beneficially in vivo to prevent 
autoimmunity (116, 117). However, their infiltration into tumour stroma raises the 
possibility that their recruitment may be a mechanism whereby CD4+ and CD8+ 
effector T cell mediated anti-tumour immune responses are abrogated (118-
121). A preponderance of CD4+ Treg cells may lead to a failure of tumour 
immunosurveillance and contribute to the progression of cancer. Two general 
subpopulations of Treg cells have been classified based on FoxP3 expression 
(Fig. 1.3). Both inhibit recognition and clearance of tumour cells by the immune 
system.  Naturally occurring Treg (nTreg) cells are derived from the thymus. 
Adaptively induced Treg (iTreg) cells differentiate from resting CD4+ T cells as 
part of the response to antigen challenge (122). The mechanisms by which Treg 
cells suppress immune responses have been described (122). These include 
physical elimination of cytotoxic cells by direct cell-to-cell contact, secretion of 
potent immunosuppressive cytokines IL-10 and TGF-β, and inhibition of 
proliferation and/or cytokine production in pathogenic T cells (122). In addition, 
Treg cells can indirectly suppress effector T cell activation via inhibition of the 
stimulatory capacity of antigen presenting cells (APCs) (122).  
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Figure 1.3: CD4+ Treg cell subpopulations. Naturally occurring Treg (nTreg) cells 
(CD4+CD25+FoxP3+) and naïve T cells (CD4+CD25-FoxP3-) are derived from the thymus. nTreg 
cells function to suppress effector CD4+ T cell proliferation. Upon activation, naïve CD4+ T cells 
can be induced to differentiate to adaptively induced Treg (iTreg) cells in the periphery. These 
iTregs have the same phenotype CD4+CD25+FoxP3+ and suppressive function. Their 
suppression mechanisms are mediated through secreting immunosuppressive cytokines IL-10 
and TGF-β.  
 
 
There are also another two populations of iTregs developed from resting 
CD4+CD25- T cells that do not express FoxP3: Tr1 (123) and Th3 (124) cells. 
Tr1 cells are defined by their ability to produce large amounts of IL-10 and low 
levels of TGF-β, whereas Th3 cells produce preferentially TGF-β. It has been 
shown that IL-10-producting Tregs can be induced by stimulation of resting 
CD4+ T cells in the presence of CD46 (the complement regulator protein) under 
homeostatic conditions (125). Tr1 cells inhibit activation of naïve and memory T 
cells and suppress Th-1 and Th-2-mediated immune responses to pathogens 
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and tumours, and their suppressive effects are mainly mediated through IL-10 
production (126). TGF-β is important for generation of Th3 cells, and their 
suppressive effects are antigen non-specific and mediated through secretion of 
TGF-β (124).   
 
Increased frequency of Treg cells in TILs compared to their prevalence in 
peripheral blood has been found in colorectal, gastric and esophageal cancer 
patients (127,128). Furthermore, the proportion of circulating Treg cells in the 




1.5.3.3 NK and NKT cells  
Innate cytotoxic lymphocytes, NK and NKT cells are present in the tumour 
microenvironment. The important functions of NK cells are to distinguish 
stressed cells (infected cells, tumour cells and cells that undergone physical or 
chemical injuries) from healthy cells, and to secrete cytokines (such as IFN-γ) to 
initiate adaptive immune response (132). NK cell infiltration appears to predict 
good prognosis in many cancers such as colorectal (133), gastric (134), lung 
(135), renal (136) and liver (137). NKT cells possess characteristics of both T 
and NK cells and play an active role in tumour immunosurveillance (132). The 
increased infiltration of Vα24+ NKT cells has been observed to be an 
independent prognostic factor for favorable prognosis in colorectal carcinomas 
(138). Conversely, a number of studies suggest that NK cells in the tumour 
microenvironment have an anergic phenotype that is induced by malignant cell-
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derived TGF-β (109).  
 
1.5.3.4 Myeloid-derived suppressor cells (MDSCs)  
MDSCs are defined as a heterogeneous population of polymorphonuclear and 
monocytic CD11b+GR1+ cells that inhibit the activation of immune cells (139).  
They originate from haematopoietic stem cells and differentiate into various 
cells, including monocytes/macrophages, DCs and granulocytes, depending on 
the types and stages of tumour and physiological conditions (139,140).   MDSCs 
can suppress CD8+ T cell activation through the expression of nitric oxide 
synthase 2 (NOS2) and arginase (ARG1) (141). In addition, they induce Treg 
cell development through secreting IL-10 and down-regulating IL-12 (142), and 
induce polarization of alternatively activated M2 macrophages through cell-
contact interaction (143).  
 
1.5.3.5 Tumour-associated macrophages (TAMs)  
Macrophages can infiltrate both primary and secondary tumours, where they 
exhibit a distinct phenotype. These cells are termed tumour-associated 
macrophages (TAMs) (144). TAMs present within the solid tumours display a 
tumour-promoting phenotype with various functions in the development of 
tumours (145, 146). These functions include stimulation of tumour cell 
proliferation and angiogenesis, promotion of malignant cell migration, invasion 
and metastasis, and suppression of anti-tumour immunity (146). The functions 
of TAMs are shown below in Figure 1.4 (146, 147). 
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Figure 1.4: The functions of TAMs in the tumour development.  These functions include 
stimulation of tumour cell proliferation and angiogenesis, promotion of malignant cell migration, 
invasion and metastasis, and suppression of anti-tumour immune responses. The mechanisms 
of immunosuppression include induction of T cell apoptosis, inhibition of cytotoxic functions of T 
cells, B cells, NK and NKT cells, induction of Treg cell population and regulatory function, and 
inhibition of NK cell activation and migration.  
 
The mechanisms of immunosuppression by TAMs include induction of T cell 
apoptosis, inhibition of cytotoxic functions of T cells, B cells, NK and NKT cells, 
induction of Treg cell population and regulatory function, and inhibition of NK cell 
activation and migration  (Fig. 1.4) (147). The relationship between the TAM 
population within tumour microenvironment and cancer patient survival may be 
complex. Pre-clinical and clinical evidence shows that a high density of TAM 
infiltration is associated with poor prognosis in various cancers, including breast, 
cervix, prostate, bladder, kidney, squamous cell carcinoma and follicular 
lymphoma (144,148). However, in contrast, they are associated with better 
prognosis in melanoma, stomach, lung and brain tumours (148). 
 
Macrophages can be broadly divided into two types: classically activated (M1) 
and alternatively activated (M2) macrophages (144, 146). M1 macrophages tend 
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to display anti-tumour effects. They are efficient immune effector cells, capable 
of killing pathogens and tumor cells, presenting antigens, and producing high 
levels of pro-inflammatory cytokines (IL-1, IL-6, and TNF-α). M2 macrophages 
tend to have pro-tumoral effects. They have poor antigen-presenting ability, are 
capable of suppressing T cell proliferation and function, and secrete high levels 
of anti-inflammatory cytokines (IL-4, IL-10, IL-13 and TGF-β) (144, 146). The 
phenotype and function of TAMs during tumour initiation differ from that during 
tumour progression. This may be compared to a switch from an M1-like to an 
M2-like phenotype. TAM polarization is dependent on the signals they receive 
from the particular tumour microenvironment in which they reside (149).  
 
1.5.3.6 Dendritic cells (DCs)  
Dendritic cells (DCs) are professional APCs of the host immune system. They 
play important roles in antigen processing and presentation, and T cell 
stimulation. DCs can be recognized by two major subsets: conventional DCs 
(cDCs) and plasmacytoid DCs (pDCs) according to the morphology, marker and 
function (150). A number of studies have demonstrated decreased presence 
and defective functionality of mature DCs in various cancer patients. Their 
abilities of tumour-associated antigen processing and T cell immune response 
stimulation are impaired (151-156). In addition, DCs at tumour sites have been 
shown to secrete TGF-β and stimulate Treg cell proliferation (157,158). They 
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1.6  Immune Response in SCLC 
 
The immune system protects the host from tumour development, growth and 
metastasis. However, most patients with SCLC demonstrate several important 
local and systemic immune defects that correlate with worse morbidity and 
mortality (160,161).  Delayed hypersensitivity skin test reactivity and a 
decreased CD4/CD8 ratio in peripheral blood lymphocytes has been observed 
to correlate with poor survival in SCLC patients (160, 161). Peripheral blood 
lymphocytes from SCLC patients show significantly reduced proliferative 
responses to phytohemagglutinin and impaired secretion of IL-2 and 
macrophage-activating factor (162). Furthermore, decrease of IL-2 secretion 
correlates with poor survival in SCLC patients (163). Histological analysis of 
lung cancer sections demonstrates that the amount of cellular infiltration of 
inflammatory cells is lowest in SCLC compared with other lung tumours (164). 
Proliferating lymphocytes isolated from tissue fragments from SCLC biopsies 
cultured in IL-2 are ineffective in lysing autologous tumour cells, though 
lymphocytes from NSCLC patients are effective (165). Alveolar macrophages 
(AM) from SCLC patients have shown impaired phagocytic function, decreased 
production of inflammatory cytokines (TNF-a, IL-1 and IL-6) (166).  In addition, 
expression of major histocompatibility complex (MHC) class II antigen and 
intercellular adhesion molecule 1 (ICAM-1) and CD83 is reduced (166).  
 
MHC class I is required for tumour antigen presentation and also subsequent 
cytotoxic T cell-mediated tumour cell lysis (167). However, the expression of 
MHC class I antigens is markedly decreased on SCLC cells and in SCLC 
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tumour sections (168). Thus down-regulation of MHC class I may represent an 
important mechanism for the development of SCLC in the early stage. The 
programmed cell death- 1 (PD-1) receptor is an immunoinhibitory receptor that 
belongs to the CD28 family. It is expressed on T cells, B cells, monocytes, NK 
cells and many TILs (169). The interaction of PD-1 and its ligand PD-L1 inhibits 
T lymphocyte proliferation, survival and effector functions, induces apoptosis of 
tumour-specific T cells and promotes the differentiation of FoxP3+ Treg cells 
(170). Cancer cells may escape immunosurveillance by expressing PD-L1 to 
down-regulate immune response. Therefore blockade of immune checkpoints 
with monoclonal antibodies has been recently developed as a new therapeutic 
strategy to improve immunity in cancers. However, in SCLC, the PD-L1 
expression is present in over 70% of tumour cells and positively correlated with 
patient survival (171). It may indicate that the expression of PD-L1 by SCLC 
tumour cells highlights the existence of the anti-tumour response, the patients 
with negative PD-L1 expression may have poor immune response and lead to 
worse survival in SCLC. Therefore, the interaction between PD-L1 expression 
and the host immune responses within the tumour microenvironment in SCLC 
patients, may differ from other tumours and need to be further studied. 
Importantly, serum from SCLC patients inhibits antibody synthesis and 
expression of T cell membrane markers (172). Similarly, treatment with 
supernatant from SCLC cell lines can suppress peripheral blood lymphocyte 
proliferation in response to phytohemagglutinin (173). These observations 
indicate that SCLC cells are capable of producing soluble immunosuppressive 
factors, which may account, at least in part, for immune deficiency in SCLC 
patients.  
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1.7 Project Aims 
 
The host immune system is now becoming an attractive target for the 
development of novel anti-cancer therapy. In SCLC, most patients are 
immunocompromised with poorly understood local and systemic immune 
defects that correlate with worse morbidity and mortality. Previous studies 
suggest that SCLC tumour cells may specifically suppress cell-mediated 
immune responses. Further understanding the mechanisms of immune 
suppression mediated by SCLC cells is required before the development of 
effective immune therapy. CD4+ T cells play a central role in coordinating anti-
tumour immune responses (174). FoxP3+ Treg cells are crucial in mediating 
suppression of anti-tumour immune responses and present at high frequencies 
in tumour tissues of various types of cancers (175,176). Macrophages are 
particular abundant in tumour tissues and present at all stages of tumour 
progression with different functions (146). The presence and effects of these 
immune cells on tumour growth have not been studied in SCLC. In this thesis, I 
investigate the interactions between tumour cells and these immune cells to 
understand mechanisms by which SCLC cells mediate immune suppression.   
 
SCLC has a very poor prognosis and only a small number of clinical markers 
are currently useful to stratify patients with SCLC into prognostic groups (177). 
Immune cells in the tumour microenvironment can eradicate malignant cells and 
control tumour growth. In SCLC, their analysis may therefore reveal novel 
prognostic markers to predict patient survival. This may assist medical decision 
making, improve future research study design and identify potential therapeutic 
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targets. However, the role of local immune cell infiltrates and specifically the 
impact of mononuclear cell and Treg cell infiltrates has not been extensively 
studied in SCLC. In this thesis, I study immune cells within the tumour 
microenvironment in biopsy samples from SCLC patients and correlate this with 




1.7.1 Hypothesis:  
 
The body of work in this thesis addresses the hypotheses that:  
 
SCLC cells mediate immunosuppression through modulating the host immune 
cell responses. Relatedly, the infiltration of immune cells within the tumour 





1.7.2 Specific Aims:  
 
The overall aims of this work were therefore to determine further mechanisms of 
immunosuppression by SCLC cells and to identify a prognostic biomarker to 
predict patient survival in SCLC.  
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The following specific aims were:  
 
1) To determine the mechanisms by which cell lines derived from SCLC 
tumours can suppress anti-tumour immune response in vitro by 
investigating:   
 
a) Whether and how SCLC cells suppress cell-mediated immune 
response; 
b) Whether SCLC cells induce Treg cell population, and identify the 
phenotype and function of these cells;  
c) Whether SCLC cells can affect macrophage polarization.  
 
 
2) To assess local immune cell infiltrates into tumour tissues and to 
correlate this with patient survival in SCLC by:  
 
a) Identifying the population and location of immune cell infiltrates within 
SCLC biopsies; 
b) Investigating whether infiltration of Treg cells (FoxP3+) and/or 
mononuclear leukocytes (CD45+) have predictive effects on SCLC 
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2.1 Cell Lines and Maintenance Cultures  
Mycoplasma-free small cell lung cancer cell lines, NCI-H69, NCI-H345 were 
purchased from ECACC (Health Protection Agency, Porton Down, UK) and NCI-
H510 from ATCC (LGC Standards, Teddington, UK). The cells were maintained 
in in HEPES buffered RPMI 1640 medium (Gibco®, Thermo Fisher Scientific) 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 5 µg/ml 
L-glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin (Gibco®, Thermo 
Fisher Scientific). SCLC cells were cultured in suspension at 2 - 5 x 105 cells/ml 
and passaged up to 10 times prior to use in 75cm2 flasks (Greiner Bio One, UK) 
at 37oC in a humidified 5% CO2 incubator.  
 
2.2  SCLC cell Conditioned Medium (CM) and Cell Lysate  
H69 and H510 cells grown as above were washed with Dulbecco's phosphate-
buffered saline (PBS) without calcium/magnesium (Ca2+ and Mg2+ free) 
(Gibco®, Thermo Fisher Scientific) and resuspended at 2.5 x 106/ml in 10 ml 
Iscove’s Modified Dulbecco’s Medium (IMDM) (Gibco®, Thermo Fisher 
Scientific) supplemented with 50 U/ml penicillin and 50µg/ml streptomycin, but 
without FBS, in 25 cm2 tissue culture flasks (Greiner Bio One, UK) for 72 hours. 
In some experiments, anti-IL-15 neutralising antibody (200 ng/ml, eBioscience), 
anti-TGF-β neutralising antibody (10 µg/ml, R&D Systems), or isotype control 
antibody was added to H69 cell culture and incubated for 72 hours. The serum-
free conditioned medium (CM) was centrifuged at 300g for 5 minutes to remove 
cells and collected prior to use in section 2.13.   
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To lyse cells, the cell pellet was resuspended in lysis buffer ((10X Cell Lysis 
Buffer: 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 
1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM 
Na3VO4, 1 µg/ml leupeptin， Cell Signaling Technology, UK) was diluted to 1X 
solution in ddH2O with 1mM Phenylmethylsulfonyl fluoride (PMSF) (Sigma-
Aldrich, UK), 1X MINI protease inhibitor cocktail tablet (Roche)),  and incubated 
for 30 minutes on ice. The cell lysates were centrifuged  (14,000g) for 10 
minutes at 4oC and supernatant was collected to use in section 2.15.  
 
2.3 Isolation of peripheral blood mononuclear cells (PBMCs)  
Human peripheral blood was obtained from normal healthy donors approved by 
Guy’s Hospital Ethics Committee, King’s College London, and full written 
informed consent was obtained from all subjects. The peripheral blood was 
layered onto LymphoprepTM (Axis-Shield, Cambridgeshire, UK). PBMCs were 
isolated by density gradient centrifugation at 2,000g for 20 minutes. In brief, the 
blood was diluted with sterile PBS (Ca2+ and Mg2+ free) at ratio 1:1. 15 ml of 
room temperature LymphoprepTM was added into 50ml FalconTM (Greiner Bio 
One, UK) tubes. 25 ml of diluted blood was carefully layered onto LymphoprepTM 
in each tube using a sterile pastette and centrifuged at 2,000g for 20 minutes 
with no brake. The white cells from the interface were removed with a sterile 
pastette and washed three times with PBS by centrifugation at 1000g for 5 
minutes to remove platelets. The cells were resuspended in complete IMDM 
(10% FBS, 50U/ml penicillin and 50µg/ml streptomycin) prior to use in sections 
2.4, 2.5 and 2.7.  
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2.4 Isolation of CD4+ T cells and naïve subset 
Purity of cell isolates was evaluated by flow cytometry. CD3+CD4+ cells were 
isolated to >95% purity from PBMCs by negative selection using CD4+ T cell 
isolation kit (Miltenyi Biotec, UK) according to the manufacturer’s instructions. 
Naïve CD4+CD45RA+ T cells were isolated to this purity from PBMCs using 
naïve T cell isolation kit II (Miltenyi Biotec) according to the manufacturer’s 
instructions. In brief, PBMCs were resuspended in 40 µl MACS buffer (PBS Ca2+ 
and Mg2+ free, with 0.5% bovine serum albumin (BSA) and 2 mM EDTA, pH 7.2, 
sterile filtered) per 107 cells and incubated with 10 µl of naïve/CD4+ T cell Biotin-
Antibody Cocktail per 107 cells for 5 minutes at 4oC. A further 30 µl of MACS 
buffer and 20 µl of anti-biotin naïve/CD4+ T cell anti-biotin MicroBead Cocktail 
were added per 107 cells and incubated for 10 minutes at 4oC. The cell 
suspension was separated with LS columns (Miltenyi Biotec) placed in the 
magnetic field of a suitable MACS separator.  The flow through of unlabelled 
cells (enriched naïve/CD4+ T cells) were collected, washed with MACS buffer 
and resuspended in complete IMDM prior to use in sections 2.8, 2.10 and 2.11.    
 
2.5 Isolation of Monocytes  
Unlabelled monocytes were isolated from PBMCs by negative selection using 
monocyte isolation kit II (Miltenyi Biotec, UK) according to the manufacturer’s 
instructions.  The purity of CD14+CD16- cells was >94%. In brief, PBMCs were 
resuspended in 30 µl MACS buffer (PBS Ca2+ and Mg2+ free, with 0.5% bovine 
serum albumin (BSA) and 2 mM EDTA, pH 7.2, sterile filtered) per 107 cells, 
blocked with Fc receptor blocking Reagent for 5 minutes, and incubated with 10 
µl of biotin-antibody cocktail per 107 cells for 10 minutes at 4oC. A further 30 µl 
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of MACS buffer and 20 µl of anti-biotin MicroBead Cocktail were added per 107 
cells and incubated for 15 minutes at 4oC. The cells were washed with 2 ml of 
MACS buffer (centrifuge at 300g for 10 mins), resuspended in 500 µl of MACS 
buffer per 108 cells and separated with LS columns (Miltenyi Biotec) placed in 
the magnetic field of a suitable MACS separator.  The unlabelled cell flow 
through (enriched monocytes) were collected, washed with MACS buffer and 
resuspended in complete IMDM prior to use in sections 2.6 and 2.12.   
 
2.6 Differentiation and Activation of Macrophages from Monocytes  
2 x 105 purified CD14+ monocytes were purified as above and plated on 6-well 
plates (GBO, UK) per well in completed IMDM, and incubated for 1 hour at 37oC 
in a humidified 5% CO2 incubator. Monocytes adhered to the tissue culture 
plastic. Non-adherent cells were removed by gently washing the monocyte 
monolayer with warm (37oC) IMDM three times. GM-CSF (100 ng/ml, R&D 
systems, UK) was added to the cells and cultured for 6 days without medium 
change to allow macrophage differentiation. To activate the immature monocyte-
derived macrophages, the medium was replaced and LPS (10 ng/ml, Sigma 
Aldrich) was added at day 7 and cells were cultured for a further 24 hours. The 
cells were harvested with Trypsin/EDTA (0.05%, Gibco®, Thermo Fisher 
Scientific) and washed (300g, 5min) with PBS, stained with appropriate 
antibodies and analysed by flow cytometry on a FACS Calibur (BD Biosciences, 
Oxford, UK) (section 2.16), or the cells were resuspended in complete IMDM 
and co-cultured with H69 SCLC cells (section 2.12).  
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2.7 Mixed Leukocyte Reactions (MLR)  
Mixed leukocyte reactions (MLRs) were established from the PBMCs of two 
separate unrelated donors prepared as described above. SCLC cells (H69, 
H345 and H510) were washed with PBS by centrifugation at 300g for 5 minutes 
and resuspended in PBS at 1 x 106 cells/ml, and incubated with mitomycin C 
(Sigma-Aldrich, UK) at 50 µg/ml for 3 hours at 37oC. It was confirmed that this 
produced the maximum suppression in SCLC cell proliferation with least loss in 
cell viability by Trypan blue solution (Sigma-Aldrich). The cells were washed 
three times in PBS (300g, 5min) prior to use and resuspended in complete 
IMDM. In a 96-well plate (GBO, UK), 5 x 104 PBMCs per donor per well were 
combined with Concanavalin (Con) A (Sigma-Aldrich, UK) at 5 µg/ml, and co-
cultured with mitomycin-C-treated SCLC cells at a 1:1 ratio (i.e. 1 x 105 mixed 
leukocytes/well and 1 x 105 SCLC cells) in 200 µl complete IMDM at 37oC in a 
humidified 5% CO2 incubator for 72 hours. Cell proliferation was assessed by 
3H-thymidine incorporation (section 2.9.1).  
 
2.8 Naïve/CD4+ T cell activation 
Purified naïve/CD4+ T cells were enriched as described above. For activation 
experiments, in 96-well plates, 2 x 105 CD4+ T cells per well were stimulated 
with immobilized anti-CD3 (0.125 µg/ml) (OKT3, pre-coated for 6 hours at 37oC) 
and soluble anti-CD28 (1 µg/ml)(CD28.2) monoclonal antibodies (both from 
eBioscience, UK) in a volume of 200 µl per well. In 24-well plates (GBO, UK), 2 
x 105 naïve/CD4+ T cells per well were stimulated with pre-coated immobilized 
anti-CD3 (1.25 µg/ml) and soluble anti-CD28 (1 µg/ml) in 1 ml per well complete 
IMDM at 37°C in 5%CO2 in a humidified incubator for 72 hours. For some 
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experiments, naïve/CD4+ T cells were activated with Dynabeads CD3/CD28 T 
cell expander (One bead per cell, Gibco®, Thermo Fisher Scientific). In others, 
the cells were treated with phorbol myristate acetate (PMA) (100 ng/ml, Sigma-
Aldrich) plus ionomycin (IONO) (50 ng/ml, Sigma-Aldrich). Cell proliferation was 
assessed by 3H-thymidine incorporation (section 2.9.1).  
 
2.9 Cell proliferation assays  
 
2.9.1 3H-thymidine incorporation 
Cells were cultured in triplicate for 48 hours and pulsed for an additional 24 
hours with 37kBq [3H]-thymidine (1 µCi, Perkin Elmer, Cambridge, UK) per well. 
Cells were then harvested with a Tomtec (Leamington Spa, UK) cell harvester 
and the radionuclide uptake was measured in a beta plate reader (Wallac, UK) 
by scintillation counting as an indicator of proliferation.  
 
2.9.2 Carboxyfluorescein diacetate succinimidyl ester (CFSE) 
incorporation  
To assess more details of CD4+ T cell proliferation, freshly isolated naïve/CD4+ 
T cells were labelled with carboxyfluorescein succinimidyl ester  (CFSE) cell 
proliferation kit  (1 µM; Molecular ProbesTM, Thermo Fisher Scientific) according 
to the manufacturer’s instructions. Briefly, isolated CD4+ T cells were incubated 
with 1 µM CFSE in pre-warmed PBS/0.1%BSA for 10 minutes at 37oC. The 
reaction was then quenched by addition of 5 volumes of ice-cold complete 
IMDM culture medium and incubated on ice for 5 minutes. The cells were 
immediately washed twice with complete IMDM, and then co-cultured with 
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SCLC cells using Transwells. After 72 hours, the cells were harvested and 
analysis of cell division was estimated by flow cytometry on a FACS Calibur (BD 
Biosciences, Oxford, UK) using FlowJo™ (Tree Star) analysis software.   
 
2.10 Co-culture of SCLC cells and CD4+ T cells 
CD4+ T cells were purified and SCLC cells were treated with mitomycin-C as 
described above. The cells were washed three times in PBS (300g, 5min) prior 
to use. In 96-well plates, 2 x 105 CD4+ T cells were activated as described 
above. 2, 4 or 8 x 105 cells/well mitomycin-C treated H69, H345 or H510 were 
co-cultured with CD4+ T cells for 72 hours at 37oC. After 48 hours 1 mCi 3H-
thymidine was added to each well. 24 hours later cells were harvested and 
cellular uptake of 3H-thymidine was assessed by liquid scintillation counting 
using a beta plate reader (Wallac, Finland) (section 2.9.1).   
 
2.11 Transwell co-culture of SCLC cells and naïve/CD4+ T cells 
For the co-culture experiments using transwells, polycarbonate 24-well transwell 
inserts (0.4 µM pore size) and receiver trays (both from Millipore, UK) were used 
to physically separate naïve/CD4+ T cells and H69 SCLC cells. 2 x 105 
naïve/CD4+ T cells were resuspended in 800 µl complete IMDM, stimulated with 
immobilized anti-CD3 (1.25 µg/ml) and soluble anti-CD28 (1 µg/ml) and added in 
the lower chambers of the plates. 200 µl complete IMDM only or containing 2, 4 
or 8 x 105 H69 SCLC cells (T cells/SCLC cell ratio of 1:1, 1:2 or 1:4) was added 
to the upper transwell chambers. The plates were incubated for 72 hours at 
37oC. The cells were harvested for cell proliferation assay by uptake of 3H-
thymidine or CFSE incorporation (section 2.9), or for Treg cell population 
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analysis by flow cytometry (section 2.16). The cell culture supernatants were 
collected for cytokines measurement by ELISAs (section 2.15).   
 
2.12  Transwell co-culture of SCLC cells and monocytes or MDMs 
1 x 105 monocytes were purified from PBMCs or 1 x 105 monocyte-derived 
macrophages (MDMs) were differentiated as described above, resuspended in 
800ul complete IMDM in 24-well plates. 200 µl complete IMDM alone or 
containing 4 x 105 H69 SCLC cells was added to the upper transwell chambers. 
After 24 hours incubation, H69 cells in transwells and cultured medium were 
removed, washed three times with PBS, and monocytes or MDMs were 
resuspended in 200 µl lysis buffer prepared as above, the cell lysates were 
collected for western blot (section 2.20). 
 
1 x 105 purified monocytes were resuspended in 800 µl complete IMDM and 
activated with LPS (10 ng/ml) in the lower chambers of 24-well plates. 200 µl 
complete IMDM alone or containing 1, 2 or 4 x 105 H69 SCLC cells was added 
to the upper transwell chambers. In some experiments, RC-3095 (1 µM, Sigma-
Aldrich) or Dimethyl sulfoxide (DMSO) (Sigm-Aldrich) was added to the culture. 
After 24 hours incubation, the supernatant was collected (300g, 5min) and TNF-
α production was measured by ELISA (section 2.15).   
 
Monocyte-derived macrophages (MDM) were differentiated as described above 
and harvested with Trypsin/EDTA (0.05%, Gibco®, Thermo Fisher Scientific) at 
day 6. 2 x 105 MDM were resuspended in 800 µl complete IMDM in the lower 
chambers of 24-well plates, stimulated with LPS (10 ng/ml), cultured alone or 
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co-cultured with 8 x 105 H69 SCLC cells in 200 µl IMDM in transwells in the 
presence of RC-3095 (1 µM, Sigma-Aldrich) or DMOS control (Sigm-Aldrich). 
Cells and supernatants were collected by centrifugation (300g, 5min) prior to 
analysis by flow cytometry (section 2.16) and ELISAs (section 2.15).  
 
2.13 Culture of naïve/CD4+ T cells with SCLC cell conditioned medium 
(CM) 
5 x 105 purified naïve/CD4+ T cells were resuspended in 600 µl complete IMDM 
and stimulated with immobilized anti-CD3 (1.25 µg/ml) and soluble anti-CD28 (1 
µg/ml) in 24-well plate. H69 and H510 SCLC cell supernatants were prepared as 
described above and serum-free CM was removed. 400 µl of H69 CM, H510 CM 
or complete IMDM was added into each well containing CD4+ T cells. In some 
experiments, H69 serum-free CM was heated to 56oC for 10 minutes or was 
further separated into fractions containing soluble molecules < 30kDa or > 
30kDa using centrifugal filter concentrators (Centricon®Plus-70, Millipore) 
according to the manufacturer’s instructions. In brief, 50 ml H69 cell culture 
medium was added to the centrifugal filter devices, centrifuged at 3,500g for 10 
minutes at room temperature. Each fraction was collected and added separately 
to the CD4+ T cell cultures. Plates were incubated for 72 hours at 37oC. The 
cells were harvested for cell proliferation assay by uptake of 3H-thymidine or 
CFSE incorporation (section 2.9), or for Treg cell population analysis by flow 
cytometry (section 2.16). The cell culture supernatants were collected for 
cytokine measurement by ELISA (section 2.15).    
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2.14 Cell culture additives   
Recombinant human IL-15 protein (rIL-15) (20 pg/ml, 20 ng/ml, 200 ng/ml, R&D 
Systems) was added as indicated to the activated naïve CD4+ T cell culture 
alone or with H510CM. IL-10 signalling was blocked with monoclonal blocking 
anti-human IL-10 Rα antibody compared to isotype control antibody (mouse 
IgG2B) at a concentration of 20 µg/ml (R&D systems). TGF-β signalling was 
blocked with monoclonal neutralising anti-TGF-β antibody (active against all 
isoforms) and compared to isotype control antibody (mouse IgG1) at a 
concentration of 10 µg/ml (R&D systems) or with 1 µM of TGF-β and activin-
signalling inhibitor SB431542 hydrate (Sigma-Aldrich) and DMSO vehicle control 
(Sigma-Aldrich). GRP signalling was blocked as indicated using a potent GRP 
receptor antagonist RC-3095  (1 µM, 5 µM, 10 µM, Sigma-Aldrich) or DMSO 
(Sigma-Aldrich) as control. IL-15 function was blocked with a monoclonal mouse 
anti-human IL15 neutralising antibody  (200 ng/ml, eBioscience) compared to 
the isotype control mouse IgG1 antibody.  
 
2.15 Measurement of cytokine production by Enzyme Linked 
Immunosorbent Assay (ELISA)   
1 x 106 H69 SCLC cells were cultured in serum-free IMDM in 24-well plates for 
72 hours, and then the supernatant was collected and centrifuged (300g, 5mins) 
prior to TGF-β1 ELISA.  
For co-culture of CD4+ T cells with SCLC cells in transwells, 2 x 105 cells CD4+ 
T cells were stimulated with anti-CD3/CD28 in 24-well plates, co-cultured with 2, 
4 or 8 x 105 live H69 SCLC cells in transwells. In some experiments, 5 x 105 
CD4+ T cells were stimulated with anti-CD3/CD28 in 24-well plates and cultured 
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with serum-free H69 CM diluted to 20% or 40%. The supernatants from CD4+ T 
cells were collected and centrifuged (300g, 5min) after 72 hours stimulation, the 
cytokines IL-10, INF-γ, IL-4, and IL-17 were all measured in the supernatants of 
co-culture of CD4+ T cells and SCLC cells, or the supernatants from CD4+ T 
cells cultured with SCLC conditioned medium by ELISA (all from R&D systems, 
UK), IL-15 by Ready-SET-Go!® (eBioscience, UK) according to the 
manufacturer’s instructions. For co-culture of monocytes or monocyte-derived 
macrophages (MDMs) with SCLC cells in transwells, 1 x 105 monocytes or 2 x 
105 MDM were co-cultured alone or with 4 x 105 or 8 x 105 SCLC cells for 24 
hours in the presence of LPS at a concentration of 10 ng/ml, the supernatants 
were collected (300g, 5min) and cytokines TNF-α, INF-γ, IL-6 and IL-10 were 
measured by ELISAs (R&D systems). The supernatants were either analysed 
immediately or stored frozen until analysis. Plates were read at 450 nm (650 nm 
reference) on a Biotek Synergy HT plate reader (Fisher Scientific, UK).  
 
2.16 Flow cytometric analysis of protein expression  
Surface marker staining used standard protocols with conjugated mouse 
monoclonal antibodies: FITC-anti-CD8 (DK25), RPE-anti-CD4 (MT310), RPE-
Cy5-anti-CD3 (UCHT1) and mouse IgG1 (DAK-GO1) isotype controls (all 
obtained from DAKO); PE-anti-CD45RA (HI100) and PE-anti-CD127 
(eBioBDR5) (both obtained from e-Bioscience).  For regulatory T cell 
(CD4+CD25+Foxp3+) staining, human Treg detection kit (Miltenyi Biotec) was 
used according to the manufacturer’s instructions. Briefly, fresh isolated, or anti-
CD3/CD28 activated alone, or anti-CD3/CD28 activated and co-cultured (with 
H69 cells or H69 CM) CD4+ T cells were stained against surface antigens with 
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FITC-anti-CD4 (VIT4) and PE-anti-CD25 (4E3) conjugated monoclonal 
antibodies. The cells were then fixed and permeabilized, blocked with Fc 
receptor (FcR) blocking reagent and stained with intracellular APC-anti-FOXP3 
(3G3) or mouse IgG1 isotype control. Alternatively, Tregs were stained with 
FITC-anti-CD4 (VIT4), PE-anti-CD127 (eBioBDR5) and APC-anti-FOXP3 (3G3). 
In some experiments, fresh isolated CD4+ T cells were labelled with CFSE as 
above, co-cultured with H69 cells at the ratio of 1:4 in transwells for 72 hours, 
then fixed and permeabilized. The cells were then treated with FcR blocking 
reagent, stained with PE-anti-mouse/human Helios protein (22F6; Biolegend, 
UK) and APC-anti-human FOXP3 (3G3) or isotype control and analyzed by flow 
cytometry.  
 
For monocyte-derived macrophage (MDM) surface marker staining, the cells 
were blocked with Fc receptor blocking solution (BioLegend, UK), and stained 
with FITC-anti-CD16 (CB16), Alexa-Fluor488 anti-CD86 (IT2.2), PE-anti-CD14 
(61D3), PE-anti-CD163 (GHI/61), PE-Cyanine7-anti-CD68 (Y1/82A), PerCP-
eFluor710-anti-CD80 (2D10.4), APC-anti-HLA-DR (LN3). APC-anti-CD206 
(19.2) (all obtained from eBioscience) or mouse IgG1 isotype control antibody. 
The cells were either analyzed immediately or fixed with 2% Paraformaldehyde 
solution (Sigma-Aldrich) for 15 minuets at room temperature and analyzed 
within 24 hours by flow cytometry.  Data were acquired on a FACS Calibur flow 
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2.17 Treg functional assay 
Naïve CD4+ T cells purified from single donors were divided into two aliquots. 
One aliquot was stimulated as above with anti-CD3/CD28 antibodies, then co-
cultured with H69 SCLC cells at 1:4 ratio in transwells for 3 days. The second 
aliquot was immediately frozen and stored at -80oC for 3 days in freezing 
medium: 40% complete IMDM, 50% FBS and 10% DMSO (Hybri-MaxTM, Sigma-
Aldrich).  
 
On day 3, frozen naïve CD4+ T cells were quickly thawed (37oC, 5 min) and 
washed three times with warm complete IMDM by centrifugation (300g, 5min). 
The cells were assessed by trypan blue assay (Sigma-Aldrich) to have > 95% 
viability. They were then labelled with CFSE. The previously activated, co-
cultured autologous CD4+ T cells were harvested and counted. 1 x 105 cells/well 
CFSE-labelled defrosted naïve CD4+ T cells were then co-cultured with 2 x 105 
cells/well of unlabelled autologous CD4+ T cells in 24-well plates in the presence 
of DynabeadsTM CD3/CD28 T cell expander (one bead per cell, Thermo Fisher 
Scientific). After 3 days, the proliferation and cell division of CFSE-labelled CD4+ 
T cells was analysed by flow cytometry.  
 
2.18 Immunohistochemistry (IHC) 
Ethical and institutional management approval for the study was obtained from 
the Lothian Research Ethics committee. 64 biopsy samples with primary lung 
SCLC from the years 1999 to 2001, for which sufficient residual material and the 
clinical data were available, were identified from the pathology archives at the 
Royal Infirmary of Edinburgh.  
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Formalin-fixed, paraffin-embedded lung tumour sections (3 µm) were de-waxed 
in xylene for 10 minutes. Tissue was rehydrated through graded ethanol (100%, 
90%, 70%, 50%, 5min each). Antigen retrieval was performed by heating 
rehydrated tissue in BORG Decloaker pH9.5 (Biocare Medical, Walnut Creek, 
CA) using a 1000W microwave oven for 10 minutes at maximum power. 
Sections were cooled in running tap water for 10 minutes and endogenous 
peroxidase was blocked in 3% hydrogen peroxide (v/v in distilled water, Sigma-
Aldrich) for 15 minutes at room temperature. Slides were mounted in a 
Sequenza® (Shandon) slide rack, washed with PBS, blocked with general 
protein block (DAKO) for 30 minutes at room temperature and followed by avidin 
block (Vector Labs) for 15 minutes at room temperature. Appropriate primary 
antibodies or isotype control antibodies were diluted in antibody diluent (DAKO): 
polyclonal rabbit ant-human CD3 (1:200 dilution, clone IS503, DAKO), 
monoclonal mouse anti-human CD4 (1:100 dilution, clone 4B12, DAKO), 
monoclonal mouse anti-human CD68 (1:100 dilution, clone PG-M1, DAKO), 
monoclonal mouse anti-human CD20cy (1:300 dilution, clone L26, DAKO), 
monoclonal mouse anti-human CD45 (1:100 dilution, clone 2B11 + PD7/26, 
DAKO), monoclonal mouse anti-human FoxP3 (1: 25 dilution, clone 236A/E7, 
eBioscience), monoclonal mouse anti-human IL-15 (1: 500 dilution, Abcam), 
polyclonal rabbit anti-human GRP-R (1:200 dilution, Thermo Fisher Scientific). 
100 µl of diluted primary antibody was added to each slide and incubated 
overnight at 4oC. Slides were then washed with PBS and blocked with biotin 
block (Vector Labs) for 15 minutes at room temperature. The detection was 
performed with biotinylated secondary antibody (100 µl of Polyclonal goat anti-
mouse, Polyclonal goat anti-rabbit, 1:400 dilution, DAKO), and incubated with a 
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preformed complex of avidin and biotinylated horseradish peroxidase 
macromolecular (Vector Labs) for 60 minutes at room temperature. The slides 
were washed with PBS, developed with 3,3V-diaminobenzidine DAB (100 µl, 
DAKO) according to the manufacturer’s instructions for 5 minutes at room 
temperature in the dark. They were washed with PBS and counterstained with 
Mayers haematoxylin (Sigma-Aldrich) for 1 minute and acid for 5 seconds, 
immersed in Scotts tap water for 3 minutes.  Dehydration was then achieved 
through graded ethanol (50%, 70%, 90%, 100%), cleared in xylene (5min each) 
and mounted with DPX mounting medium (Thermo Fisher Scientific). For IL-15 
IHC staining on cytospins, H69 and H510 cells were washed with PBS and spun 
on slides (200 cells/mm3, 1000rpm, 5min). The cells were air-dried and fixed in 
90% anhydrous acetone/10% methanol for 20 minutes at room temperature. 
The slides were washed and IL-15 immunostaining was performed as described 
above but without antigen retrieval. Stained slides were viewed with a Leica 
DM1000 microscope at 100-400X magnifications and photographed with a Leica 
DFC400 digital camera (both from Leica Microsystems, UK).  
 
2.19 Immunofluorescence  
SCLC tumour sections were de-waxed, rehydrated, and antigen retrieval was 
performed as described above. The sections were blocked with 5% goat serum 
for 30 minutes at room temperature，washed with PBS and incubated with 
polyclonal rabbit ant-human CD3 (1:200 dilution, clone IS503, DAKO) and 
monoclonal mouse anti-human Foxp3 antibody monoclonal mouse anti-human 
FoxP3 (1:25 dilution, clone 236A/E7, eBioscience). 100 µl of each primary 
antibody diluted in antibody diluent (DAKO) was added to the slide and 
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incubated for 1 hour at room temperature in the dark. The slides were washed 
with PBS and incubated with 100 µl of secondary antibodies Alexa-488 goat 
anti-rabbit IgG and Alexa-568 goat anti-mouse IgG in antibody diluent (1:1000 
dilution, Thermo Fisher Scientific) for 30 minutes at room temperature in the 
dark, and followed by 100 µl of 4,6-diamidino-2-phenylindole (DAPI) (0.1 µg/ml, 
Thermo Fisher Scientific) to stain nuclei for 5 seconds and washed with PBS. 
The sections were mounted in aqueous mounting medium (DAKO) and 
analysed on a Leica TCS SP5 confocal microscope.  
 
 
2.20 Western Blot  
The cells were washed twice with PBS (300g, 5min), resuspended in 1X lysis 
buffer (Cell Signalling Technology) with 1mM PMSF (Sigma-Aldrich), 1X MINI 
protease inhibitor cocktail tablet (Roche), and agitated on ice for 30 minutes. 
Protein concentration in the whole cell lysates was measured using BCA protein 
assay reagent (PierceTM, Thermo Fisher Scientific) according to the 
manufacturer’s instructions. Balanced whole cell lysates were resuspended in 
4X premixed Laemmli protein sample buffer (277.8 mM Tris-HCl, pH 6.8, 4.4% 
LDS, 44.4% (w/v) glycerol, 0.02% bromophenol blue, Bio-Rad, UK) and 
denatured by heating to 95oC for 5 minutes. Lysates (15 µg protein per lane) 
were resolved on 10% Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) (NuPAGETM, Thermo Fisher Scientific)  (120V, 
40mA, 90min) and transferred onto 0.45 mm nitrocellulose membranes (Bio-
Rad) (100V, 390mA, 60min). Blots were blocked with blocking buffer (5% w/v 
milk in 1X TBS, 0.1% Tween20) for 60 minutes at room temperature and 
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incubated with appropriate primary antibodies: polyclonal rabbit anti-human 
GRP-R (1:1000 dilution, Thermo Fisher Scientific), rabbit anti-human phospho-
Akt (Ser473) (1:1000 dilution, Cell Signalling Technology), rabbit anti-human Akt 
(1:1000 dilution, Cell Signalling Technology) and rabbit anti-human 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:3000 dilution, Cell 
Signalling Technology) diluted in blocking buffer overnight at 4oC. The 
membranes were incubated with horseradish peroxidase-labelled polyclonal 
goat anti-rabbit secondary antibody (1:3000 dilution, DAKO) diluted in blocking 
buffer for 60min at room temperature. The blots were detected using ECL 
western blotting detection reagent (Amersham) according the manufacturers 
instructions and visualised on the Bio-Rad ChemiDocTM MP System (Bio-Rad).   
 
2.21 Cell viability determination by MTT assay  
A (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) cell 
proliferation assay kit (Vybrant®, Thermo Fisher Scientific) was used to 
determine cell viability according to the manufacturer’s instructions. The 24-well 
culture plates containing cells were centrifuged (300g, 5min) at room 
temperature; the culture medium was carefully removed and replaced with 500 
µl complete medium. 50 µl of 5 mg/ml MTT stock solution was added to each 
well and incubated for 2 hours at 37°C. The medium containing MTT was 
discarded by centrifugation (300g, 5min) and the plates were left to dry for 30 
minutes at room temperature. 500 µl of DMSO (Sigma-Aldrich) was added to 
each well, mixed thoroughly and incubated for 10 minutes at 37°C. 50µl of each 
sample was transferred in 96-well plates and absorbance at 560 nm was 
measured on a Biotek Synergy HT plate reader (Fisher Scientific, UK).  
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2.22 Microarray analysis  
The comparative analysis was conducted by the bioinformatics team in the BHF 
Centre for Research Excellence, University of Edinburgh. Expression data were 
downloaded from the Gene Expression Omnibus. All result sets were derived 
from variants of the Affymetrix Human GenomeU133 GeneChip. Expression 
values were converted to the linear scale where appropriate. Annotation for the 
probe identifiers on these chips was derived from appropriate annotation 
packages provided by the Bioconductor software suite (www.bioconductor.org). 
All data were uploaded to a relational database and examined by use of a web-
based query builder. Although the vast majority of probe identifiers were 
comparable between chips, this web interface allowed qualitative comparison of 
expression for different probe IDs mapping to the same gene via their gene IDs 
from Entrez (PMID 15608257). Because these data were derived from disparate 
experiments and not cross-normalised, this methodology allows only for a 
coarse comparison of expression levels. 
 
2.23 Statistical analysis  
Data were expressed as the standard error of the mean (± SEM). The statistical 
significance of the difference between two groups was performed using the 
Student’s t test. For multiple group comparisons, one-way analysis of variance 
(ANOVA) with Tukey’s post test was performed. Correlation between values 
was evaluated using nonparametric Spearman’s rank correlation. All the 
statistical analysis was determined using GraphPadTM Prism 6 (Graph Software, 
San Diego, CA, USA) and probability values (p) of less than 0.05 were 
considered statistically significant.  
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3.1 Introduction  
 
The immune system protects the host from tumour development, growth and 
metastasis, and has become an attractive target for the development of novel 
immunotherapy for cancer (178). To this end clinical trials of anti-tumour 
vaccines have been conducted. These have demonstrated that anti-tumour 
immunity can be induced or enhanced with beneficial effects in multiple cancers, 
however success rates remain limited (179,180). This may relate to insufficient 
presentation of appropriate “danger signals” needed to activate the immune 
system by tumour cells (181). Relatedly, tumour cells may remain so similar to 
the normal cells from which they were derived that they resist full recognition by 
the immune system (182). Once an immune response has been induced 
however, tumour cells may still escape from effective immunosurveillance, 
suggesting tumour-induced alterations to the patient’s immune system may 
subvert or suppress anti-tumour responses within tumour microenvironment and 
thus facilitating tumour growth (178,179).    
 
SCLC may represent a good example of such disease behavior. In SCLC, most 
patients are immunocompromised with poorly understood local and systemic 
immune defects that correlate with worse morbidity and mortality. Indeed, 
delayed hypersensitivity skin test reactivity and a decreased CD4/CD8 ratio in 
peripheral blood lymphocytes are associated with a worse prognosis in SCLC 
(160,161).  Similarly, the peripheral blood lymphocytes from SCLC patients 
demonstrate significantly reduced proliferative responses to phytohemagglutinin 
and impaired secretion of IL-2 and macrophage-activating factor (162). In 
addition, proliferating lymphocytes isolated from tissue fragments from lung 
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biopsies of SCLC patients and cultured in IL-2 are ineffective in lysing 
autologous tumour cells. Conversely, lymphocytes from NSCLC patients are 
effective (165). Interestingly, the serum extracted from SCLC patients has been 
demonstrated to inhibit antibody synthesis and expression of T-cell membrane 
markers (172), and the supernatants from SCLC cell lines can suppress PBL 
proliferation in response to phytohemagglutinin or concanavalin A (173). Taken 
together these data support the hypothesis that SCLC cells may specifically 
suppress cell-mediated immune responses.  
 
Therefore, further understanding of the mechanism by which SCLC cells 
suppress the host immune response is likely required to aid the development of 
truly effective immunotherapy for SCLC. CD4+ T cells have been shown to play 
a central role in anti-tumour immune responses (174). In vivo vaccination 
tumour challenge experiments demonstrate that immunization of CD4−/− 
knockout mice fail to prime a systemic immune response capable of rejecting 
this tumor challenge. In contrast, a significant fraction of CD8-/- knockout mice 
mount successful tumour rejection responses (174). These data suggest that 
anti-tumour immunity requires coordination by CD4+-dependent effector cells. I 
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3.2 Results  
 
 
3.2.1 SCLC cells suppress proliferation of a Mixed Leukocyte Reaction. 
 
 
The mixed leukocyte reaction (MLR) is driven by recognition of disparate MHC-II 
antigens on antigen-presenting cells, by CD4+ T cells. It is a widely used in vitro 
assay for functional studies of cellular immunity (183). It was therefore used to 
determine whether the local interaction of SCLC cells with immune cells could 
suppress cell-mediated immune responses. MLRs were established by 
combining equal numbers of PBMCs from two separate donors treated with Con 
A to stimulate the cells. The MLRs were then co-cultured with H69, H345 or 
H510 SCLC cells, treated with mitomycin C to stop their proliferation. 
Proliferation of responder cells within each MLR was determined at 72 hours by 
measuring uptake of 3H-thymidine.  
 
As expected, MLRs stimulated with Con A (5 mg/ml) actively incorporated 3H-
thymidine at 72 hours, whilst SCLC cell lines (H69, H345 and H510) did not (Fig. 
3.1). Interestingly, co-culture of mitomycin C-treated H69 and H345 SCLC cells 
significantly reduced 3H-thymidine uptake in MLR, whilst H510 cells did not (Fig. 
3.1). These data therefore suggest that MLR suppression is not due to non-
specific effects of co-culture such as use of nutrients by SCLC cells or toxic 
suppression by mitomycin C. Instead they indicate that some SCLC cell lines 
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Figure 3.1:  SCLC cells suppress proliferation of a Mixed Leukocyte Reaction. The experiments 
were performed as described in section 2.7 Chapter 2. Cell proliferation was assessed by 3H-
thymidine uptake (counts per minute; cpm) by the responder cells (mean ± SEM, n=7 
experiments). * Indicates p <0.05 and *** p <0.0001.  
 
 
3.2.2 H69 SCLC cells suppress proliferation of CD4+ T cells. 
 
The mixed leukocyte reaction involves many different cell types. For anti-tumour 
immune responses CD4+ T cells are believed to be critical (174,184). 
Consequently suppression of CD4+ proliferation and/or modulation of their 
immune behaviour may be an effective mechanism by which tumour cells can 
evade such responses. Therefore, to test this hypothesis in the context of the 
differential immunomodulatory effects of SCLC co-cultures with MLRs, the 
effects of different SCLC cell lines on CD4+ T cells were next studied.  
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To this end, a novel in vitro co-culture system of SCLC cell lines and CD4+ T 
cells was established. CD4+ T cells were first isolated and purified to > 95% 
homogeneity (Fig. 3.2A). Proliferation of the CD4+ T cells following activation 
with anti-CD3/CD28 and of H69, H345 and H510 SCLC cell lines treated with 
mitomycin-C either alone or in combinations of stimulated CD4+ T cells was 
assessed. As expected, CD4+ T cells activated with anti-CD3/CD28 produced a 
marked uptake of 3H-thymidine, whilst the SCLC cell lines treated with 
mitomycin-C had no 3H-thymidine uptake. The co-culture studies followed the 
same pattern of differential immunomodulation between SCLC lines treated with 
mitomycin-C as was observed for MLRs with PBMCs. Co-culture of activated 
CD4+ T cells with H69 cells significantly reduced 3H-thymidine uptake (Fig. 3.2B 
and 3.2C). Although co-culture with H345 cells also reduced CD4+ T cells 3H-
thymidine uptake by CD4+ T cells at day 3, the difference between the means 
was not significant (Fig. 3.2B). H510 SCLC cells had no observable effect on 
CD4+ T cell proliferation in response to anti-CD3/CD28 (Fig. 3.2B). The data 
demonstrate that H69 SCLC cells can inhibit CD4+ T cell proliferation whilst 
H510 cells cannot.  
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Figure 3.2: H69 SCLC cells suppress proliferation of CD4+ T cells. The experiments were 
performed as described in section 2.10 Chapter 2. The data shows the proliferation of CD4+ T 
cells alone or in co-culture with SCLC cell lines. (A) Representative flow cytometry shows the 
populations of purified CD3+CD4+ T cells and CD4+CD8- T cells. (B) Mean 3H-thymidine uptake 
(counts per minute; cpm) ± SEM by SCLC cells and activated CD4+ T cells culture alone or with 
SCLC cell lines (H69 n=12, H345 n=9, H510 n=6).  ** Indicates p <0.01 (t-test). (C) Uptake of 
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3H-thymidine by activated CD4+ T cells cultured alone or with equal number of H69 cells (mean 
± SEM, n=12 experiments).  *** Indicates p <0.0001 (one-way ANOVA).  
 
 
3.2.3 H69 SCLC cells suppress CD4+ T cell proliferation in a dose-
dependent fashion.  
 
In the tumour microenvironment, the ratio of SCLC cells to CD4+ T cells is 
frequently greater than 1:1 (Fig. 6.1).  To investigate whether SCLC cells 
suppress the CD4+ T cell proliferation in a dose-dependent fashion, CD4+ T cells 
were co-cultured with increased ratios (CD4:H69 ratio: 1:1; 1:2; 1:4) of 
mitomycin C treated H69 SCLC cells. As expected, CD4+ T cells stimulated with 
anti-CD3/CD28 alone produced active uptake of 3H-thymidine, and co-culture 
with H69 SCLC cells at the ratio of 1:1 resulted in a non-significant reduction in 
CD4+ T cell proliferation (Fig. 3.3A). However, importantly, co-culture with 
increased ratios (CD4:H69 ratio: 1:2 and 1:4) of H69 SCLC cells significantly 
suppressed CD4+ T cell 3H-thymidine uptake compared to CD4+ T cells alone 
(Fig. 3.3A).   
 
1:1 co-culture of CD4+ T cell with equal numbers of H345 and H510 did not 
show significant effects in reducing proliferation (Fig. 3.2B). However, given the 
dose-dependent of such effects with H69 cell co-culture, it was therefore 
important to address whether greater numbers of these SCLC cell lines could 
suppress CD4+ T cell proliferation. Co-culture of CD4+ T cells in a 1:4 ratio with 
H345 SCLC cells significantly reduced CD4+ T cell 3H-thymidine uptake 
compared to CD4+ T cells alone (Fig. 3.3B). This was consistent with the non-
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significant trend to suppression of CD4+ T cell proliferation observed with 1:1 co-
culture with H345 cells (Fig. 3.2B). Conversely, 1:4 co-culture with H510 cells 
continued to show no indication of a suppressive effect upon CD4+ T cell 
proliferation  (Fig. 3.3B). 
 
 
Figure 3.3: H69 SCLC cells suppress CD4+ T cell proliferation in a dose-dependent fashion. The 
experiments were performed as described in section 2.10 Chapter 2. (A) Uptake of 3H-thymidine 
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(counts per minute; cpm) by CD4+ T cells cultured alone or with H69 SCLC cells (CD4: H69 1:1. 
1:2, 1:4) (mean ± SEM, n=6 experiments). ** Indicates p <0.01 and *** p <0.0001. (B) Uptake of 
3H-thymidine (counts per minute; cpm) by CD4+ T cells cultured alone or with H69, H345 or 
H510 SCLC cells (mean ± SEM, n=6 H69, n=4 H345 and n=4 H510). * Indicates p <0.05 and *** 
p <0.0001.  
 
 
3.2.4 Transwell co-culture of H69 SCLC cells suppresses CD4+ T cell    
proliferation.  
 
I next investigated whether H69 SCLC cells suppressed CD4+ T cell proliferation 
through contact-dependent inhibition or by the effects of secreted paracrine 
factors. This was assessed by modified co-culture experiments using transwell 
inserts that prevent direct contact between CD4+ T cells and live H69 SCLC 
cells in the culture. CD4+ T cells were stimulated with anti-CD3/CD28, cultured 
alone or co-cultured with live H69 cells at T cell to H69 cell ratios 1:1, 1:2 and 
1:4. After 72 hours, the transwell inserts and their SCLC cell contents were 
removed and CD4+ T cell proliferation was measured by uptake of 3H-thymidine. 
Co-culture with increased ratios of H69 cells in transwells significantly reduced 
the proliferation of activated CD4+ T cells at a 1:1 ratio and this effect was 
increased in a dose dependent manner (Fig. 3.4). These effects were highly 
similar to those observed with unsegregated co-culture (Fig. 3.3). The data 
therefore indicate that H69 SCLC cells inhibit CD4+ T cell proliferation 
predominantly due to the paracrine effects of soluble factors produced by H69 
cells rather than in a contact-dependent manner. 
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Figure 3.4: Transwell co-culture of H69 SCLC cells suppresses CD4+ T cell proliferation. The 
experiments were performed as described in section 2.11 Chapter 2. Uptake of 3H-thymidine 
(counts per minute; cpm) by CD4+ T cells (mean ± SEM, n=9 experiments). *** Indicates p 
<0.0001. The raw data values are listed in table 3.4.  
 
3.2.5 H69 SCLC conditioned medium (CM) suppresses CD4+ T cell    
proliferation.  
 
I next wished to determine whether the soluble factors mediating the 
suppression of CD4+ T cell proliferation were constitutively produced by H69 
cells. Serum-free conditioned medium from H69 or H510 cell culture was 
therefore added to activated CD4+ T cell culture. Replacement of 40% of the 
culture medium with H510 cell culture supernatant did not affect CD4+ T cell 
proliferation whilst replacement with H69 supernatant did (Fig. 3.5A). These 
data indicate that H69 SCLC cells continuously produce soluble factors that are 
able to suppress CD4+ T cell proliferation. These effects were dose-dependent 
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with a significant (p < 0.05) difference between the degrees of suppression 
observed when 20% and 40% of the media were replaced (Fig. 3.5B). The 
consistent lack of any observable effect with H510 co-cultures or supernatant is 
most simply rationalised by the hypothesis that the soluble factors secreted by 
H69 SCLC cells are not sufficiently secreted by H510 cells. By the same logic, 
H345 cells might be predicted to secrete such factors at levels intermediate 
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Figure 3.5: H69 SCLC cell conditioned medium (CM) supresses CD4+ T cell proliferation. The 
experiments were performed as described in section 2.13 Chapter 2. (A) Uptake of 3H-thymidine 
(counts per minute; cpm) by CD4+ T cells cultured alone or with 40% of H510CM or H69CM 
(mean ± SEM, n=7 experiments). *** Indicates p <0.0001. (B) Uptake of 3H-thymidine (counts 
per minute; cpm) by CD4+ T cells cultured alone or with 40% of PBS, 20% or 40% H69CM 
(mean ± SEM, n=7 experiments). * Indicates p <0.05 and *** p <0.0001.  
 
 
3.2.6 The suppression of CD4+ T cell proliferation is regardless of the   
mechanism of stimulation. 
 
Proliferation of CD4+ T cells depends upon stimulation of both T cell receptor 
(TcR) and co-stimulatory signals. To assess whether H69 SCLC cell mediated 
inhibition of this process only occurs in the context of TcR stimulation (i.e. 
treatment with anti-CD3/CD28).  This was also assessed when CD4+ T cells 
were stimulated with PMA (an activator of protein kinase C (PKC)) plus IONO (a 
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Ca2+ ionophore and mitogenic for PBMC). Such treatment (PMA/IONO) has 
been show to trigger human T cell activation and proliferation (185). With PMA 
plus IONO stimulation, H69CM showed the same suppressive effect on CD4+ T 
cell proliferation compared with anti-CD3/CD28 stimulation (Fig. 3.6). The data 
indicate that inhibition of CD4+ T cell proliferation by factors secreted by H69 




Figure 3.6: H69CM induced-suppression of CD4+ T cell proliferation occurs in diverse 
stimulatory contexts. The cell proliferation was assessed by the uptake of 3H-thymidine (counts 
per minute; cpm) by CD4+ T cells with different stimulations in the presence of 40% H510CM or 





	   82	  
3.2.7 H69 SCLC cells produced soluble molecules that suppress CD4+ T 
cell proliferation are less than 30kDa and heat stable.  
 
To further investigate the nature of the soluble molecules, the ability of H69 
supernatant to suppress CD4+ T cell proliferation following either fraction on the 
basis of solute size, or heating, was assessed. The supernatant was filtered into 
fractions containing and excluding solutes > 30kDa. Fascinatingly the filtrate (i.e. 
enriched for solutes < 30kDa) retained the same ability to suppress proliferation 
as the unfractionated supernatant, whilst the remaining fraction did not (Fig. 
3.7). These data indicate that the soluble factor(s) secreted by H69 cells is/are < 
30kDa in size. Some cytokines have been shown to be resistant to inactivation 
by heat (186). Suppressive activity was similarly preserved following heating 
(56oC for 10 minutes), indicating the property was due to one or more relatively 
thermostable factors. Together these findings suggest that small, heat stable 
cytokines may be candidate factors mediating the suppressive effect of H69 
SCLC cells upon CD4+ T cell proliferation. 
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Figure 3.7: H69 SCLC cells produced soluble molecules that suppress CD4+ T cell proliferation 
are <30kDa and heat stable. The experiments were performed as described in section 2.13 
Chapter 2.  Bar graph shows uptake of 3H-thymidine (counts per minute; cpm) by CD4+ T cells 




3.2.8 H69 SCLC cells inhibit CD4+ T cell proliferation by preventing 
activated CD4+ T cells from entering the cell cycle.  
 
To determine the percentage of dividing cells and numbers of cell divisions of 
the proliferation block mediated by the soluble molecule secreted by H69 SCLC 
cells, CFSE staining was performed. CD4+ T cells were labelled with CFSE cell 
tracking dye immediately after purification, stimulated with anti-CD3/CD28 and 
co-cultured with SCLC cells in transwells at a ratio of 1:4 for 72 hours at 37oC. 
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When cells divide, half of the fluorescent CFSE is transferred to daughter cells, 
allowing estimation of divisions by flow cytometry.  
 
Consistent with the preceding data on CD4+ T cell proliferation, the total 
percentage of activated CD4+ T cells entering divisions was significantly 
reduced when co-cultured with H69 cells compared to monoculture (Fig. 3.8A 
and 3.8B). The proportions of activated CD4+ T cells undergoing only a single 
division was higher in co-culture with H69 cells compared to the control. 
Conversely, the fractions of cells going on to two and three divisions were 
significantly reduced (Fig. 3.8C). The data suggest that the soluble factors 
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Figure 3.8: H69 SCLC cells inhibit CD4+ T cell proliferation through preventing activated CD4+ T 
cells from entering the cell cycle. The experiments were performed as described in section 2.9.2 
Chapter 2. (A) Representative flow cytometry demonstrates the total percentage of dividing 
CD4+ T cells. (B) The percentage of dividing CD4+ T cells (mean ± SEM, n=4 experiments). ** 
Indicates p <0.01. (C) The percentage of CD4+ T cells undergoing a single, two and three 
division cycles (mean ± SEM, n=4 experiments). ** Indicates p <0.01 and *** p <0.0001.  
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3.2.9 H69 SCLC cells suppress IL-17 but not IL-2, IFN-γ or IL-4 production.  
 
IL-2 is a potent T cell growth factor and can induce T cell expansion in vitro 
(187,188). IFN-γ and IL-4 are critical cytokines initiating the downstream 
signalling cascade to differentiate into Th1 and Th2 CD4+ lineage cells 
respectively (189). IL-17 is produced by Th17 cells, which are a separate CD4+ 
effector T helper cell subset (190). To determine whether the suppression of 
activated CD4+ T cell proliferation was accompanied by changes in production 
of these cytokines, the levels at which they were released into cell culture 
supernatants were therefore examined.  
 
Co-culture of activated CD4+ T cells with H69 SCLC cells at 1:1 – 1:4 ratios did 
not significantly affect the levels of IL-2 (Fig. 3.9A), IFN-γ (Fig. 3.9B), or IL-4 
(Fig. 3.9C) secreted into the supernatant. Interestingly, co-culture of activated 
CD4+ T cells in 1:2 or 1:4 ratios with H69 cells resulted in significantly reduced 
IL-17 secretion (Fig. 3.9D). These data suggest that H69 SCLC cells do not 
readily induce a shift to a Th1 or Th2 phenotype in activated CD4+ T cells in 
vitro, but may suppress a Th17 response.   
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Figure 3.9: H69 SCLC cells suppress IL-17 but not IL-2, IFN-γ or IL-4 production. Cytokine 
production was measured as described in section 2.15 Chapter 2. Bar graphs show the 
concentration of IL-2 (A), INF-γ (B), IL-4 (C) and IL-17 (D) released by CD4+ T cells in the 
supernatants (mean ± SEM, n=6 experiments). ** Indicates p < 0.01.  
 
 
3.2.10 H69 SCLC cells and culture medium induce increased IL-10 
production.  
 
TGF-β and IL-10 are potent immunosuppressive cytokines and play a key role in 
tumour pathogenesis (191, 192). They induce CD4+CD25+ regulatory T (Treg) 
cells that can suppress activation and proliferation of effector T cells (193-195). 
To investigate whether the suppressed CD4+ T cell proliferation was 
accompanied by changes in TGF-β1 or IL-10 release, ELISAs were performed 
on the supernatants of activated CD4+ T cells co-cultured with different ratios of 
H69 cells.  
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TGF-β1 secretion by H69 cells in serum-free conditioned medium was at low 
levels (Active: 29.53 ± 2.67 pg/ml, Latent: 75.66 ± 2.89 pg/ml, mean of n=5 
experiments ± SEM) (Fig. 3.10A). However, TGF-β1 levels in the supernatants 
from co-culture of H69 SCLC cells with activated CD4+ T cells were below the 
detection limit. The lack of detection of TGF-β1 in co-culture may be due to 
consumption by the CD4+ T cells upon activation, suggesting that there may be 
an interaction between CD4+ T cells and tumour cells.  
 
Non-stimulated CD4+ T cells or H69 cells did not produce IL-10 in the cell 
culture (Fig. 3.10B). However, activated CD4+ T cells co-cultured with H69 
SCLC cells produced significantly greater amounts of IL-10 in a dose-dependent 
fashion compared to activated CD4+ T cells cultured alone (Fig. 3.10B). In 
addition, replacement of 20-40% of culture medium with H69, but not H510, cell 
culture supernatant also significantly increased IL-10 secretion in CD4+ T cell 
cultures (Fig. 3.10C). The data suggest that the soluble factors produced by H69 
SCLC cells can induce increased IL-10 production from activated CD4+ T cells 
contributing to Treg cell population and suppression of CD4+ T cell proliferation. 
These factors may include TGF-β1.  
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Figure 3.10: H69 SCLC cells and culture medium induce increased IL-10 production. Cytokine 
production was measured by ELISAs. (A) The active and latent TGF-β1 concentration in H69CM 
assessed by ELISA (mean ± SEM, n=5 experiments). ** Indicates p < 0.01. (B) The 
concentration of IL-10 released by CD4+ T cells in the supernatants assessed by ELISA (mean ± 
SEM, n=6 experiments). * Indicates p < 0.05 and *** p < 0.0001. (C) The concentration of IL-10 
released by CD4+ T cells in the supernatants (mean ± SEM, n=6 experiments). * Indicates p < 
0.05 and *** p < 0.0001.  
 
 
3.2.11 Suppression of CD4+ T cells by H69 cells is independent of both IL-
10 and TGF-β.  
 
To determine whether increased production of IL-10 directly contributes to the 
suppression of activated CD4+ T cell proliferation, the effects of IL-10 function 
were neutralized using an anti-IL-10 receptor blocking antibody. This 
intervention did not affect the suppressed proliferation of activated CD4+ T cells 
mediated by H69 SCLC cells  (Fig. 3.11A). Similarly, anti-IL-10 receptor blocking 
antibody did not reverse the inhibition of activated CD4+ T cell proliferation 
mediated by H69 culture supernatant (Fig. 3.11B). The data therefore indicate 
that although H69 SCLC cells secrete factors that both increase IL-10 secretion 
and suppress CD4+ T cell proliferation, IL-10 is not essential for suppression of 
proliferation.  
 
Similarly, to assess whether TGF-β secretion by H69 SCLC cells was 
responsible for the suppression of CD4+ T cell proliferation, the effect of a TGF-
β neutralizing antibody was assessed. Anti-TGF-β neutralizing antibody did not 
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abrogate the suppression of CD4+ T cell proliferation mediated by H69 culture 
supernatant (Fig. 3.11C). The data suggest that the suppressive effect on CD4+ 
T cell proliferation is TGF-β independent.  
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Figure 3.11: Suppression of CD4+ T cells by H69 cells is independent of both IL-10 and TGF-β. 
An anti-IL-10 receptor blocking antibody or a TGF-β neutralizing antibody or isotype control 
antibodies were added to CD4+ T cell culture.  (A) Uptake of 3H-thymidine (counts per minute; 
cpm) by CD4+ T cells co-cultured with H69 cells in the presence of an anti-IL-10 receptor 
blocking antibody or isotype control (mean ± SEM, n=3 experiments). * Indicates p < 0.05 and 
*** p < 0.0001. (B) Uptake of 3H-thymidine by CD4+ T cells cultured with 40% H69CM in the 
presence of an anti-IL-10 receptor blocking antibody or isotype control  (mean ± SEM, n=3 
experiments). *** Indicates p < 0.0001. (C) Uptake of 3H-thymidine by CD4+ T cells cultured with 
40% H69CM in the presence of a TGF-β neutralizing antibody or isotype control 
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3.3 Discussion  
 
The local host immune response controls tumour growth and eradicates 
malignant cells, and thus has been employed to develop novel anti-cancer 
therapies. However, previous studies have suggested that SCLC cells can 
suppress cell-mediated immune reactions (162,165,173).  CD4+ T cells play 
central roles in anti-tumour immune responses (174, 184). I have therefore 
studied the effect of three different SCLC cell lines upon CD4+ T cell mediated 
PBMC behaviour in MLR assays and established unsegregated and segregated 
CD4+ T cell:SCLC cell co-culture systems. These have allowed me to assess 
whether SCLC cells could affect local immune cell behaviour and, if so, to 
dissect mechanistic factors.  
 
The data in this chapter demonstrate that H69 and H345 SCLC cells can inhibit 
the proliferation of an MLR whilst H510 cannot. This suggests that SCLC cell 
lines derived from different patients specifically suppress cell-mediated immune 
responses in leukocytes derived from healthy donors to varying degrees. 
Therefore the differences in cellular immune responses observed in SCLC 
patients in vivo may be mediated by tumour cell-derived factors and not solely 
arise from differences in the pre-existing host immunity.  The data in this chapter 
further demonstrate that H69 cells suppress CD4+ T cell proliferation in a dose 
dependent fashion whilst H510 cells have no suppressive effect. H345 cells 
inhibit CD4+ T cell proliferation only at a higher ratio (CD4:H345 1:4), consistent 
with a general trend of an intermediate level of immunosuppressive effects 
between those H69 and H510 cells.  
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H69 cell culture supernatant inhibits CD4+ T cell proliferation in response to both 
T cell receptor mediated activation and mitogenic stimulation, indicating that the 
suppressive effect is independent of stimulation mode. H69 SCLC cells inhibit 
CD4+ T cell proliferation by preventing activated CD4+ T cells from entering the 
cell cycle (Fig. 3.8). Such suppression does not depend upon cell-contact and 
appears predominantly mediated by soluble factors (Fig. 3.4 and 3.5). The data 
indicate the secreted soluble factors are <30kDa in size and heat stable. Small 
and heat stable cytokines are therefore candidate mediators of the suppressive 
effect. Together these findings represent a mechanism by which SCLC cells 
evade or subvert cell-mediated immunity through secreting soluble molecules to 
suppress CD4+ T cell proliferation in response to stimulation.  
 
IL-2 is an important stimulus to CD4+ T cell proliferation and is secreted in 
response to activation (187, 188). Previous studies demonstrated that the 
significantly reduced proliferative ability of tumour-infiltrating lymphocytes was 
associated with reduction of IL-2 release in other tumours (196,197). In SCLC, 
peripheral blood lymphocytes from patients have been shown to be less 
proliferative with reduced secretion of IL-2 in response to stimulation, and 
decreased IL-2 production correlates with poor survival (162,163). The data in 
this chapter indicate that H69 SCLC cell mediated suppression of CD4+ T cell 
proliferation is not associated with reduction of IL-2 secretion, suggesting that 
the mechanism of suppression is independent of IL-2 release.  
 
Furthermore, H69 SCLC cells do not affect IFN-γ or IL-4 secreted by CD4+ T 
cells, but reduce IL-17 secretion that is a production of Th17 cells, suggesting 
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that SCLC cells may suppress a Th17 response. Previous studies have 
demonstrated that Th17 cells are present in the tumour microenvironment in 
various human cancers (198, 199). However, the effect of Th17 cells in tumours 
is pleiotropic. They can either promote protective anti-tumour immune 
responses (200-202) or suppress immune system and contribute to  tumour 
growth (203-205). The effect of IL-17 in SCLC pathogenesis is therefore 
interesting and merits further investigation.  
 
TGF-β and IL-10 are potent immunosuppressive cytokines that have molecular 
weight less than 30kDa and play a key role in tumour pathogenesis (191,192). 
They can be produced by tumour cells and have been shown to impair the 
proliferation, cytokine production and migratory capacities of effector T cells, 
suppress the functions of antigen presenting cells, and induce regulatory T 
(Treg) cells (206-208). TGF-β is detected at low levels in both active and latent 
forms from H69 culture supernatant. However, the level of TGF-β in the 
supernatant from co-culture of H69 cells with activated CD4+ T cells is below the 
detection limit (<31.25 pg/ml), suggesting that TGF-β may be consumed by the 
T cells. Interestingly, H69 SCLC cells do not produce IL-10, but IL-10 secretion 
is significantly increased by co-culture of activated CD4+ T cells with H69 cells in 
a dose-dependent fashion or with H69 culture supernatant. Therefore H69 
SCLC cells may suppress cell-mediated immune responses may be through the 
release of TGF-β or by induction of IL-10 secretion from activated CD4+ T cells 
to inhibit further CD4+ T cell proliferation.  
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Previously published data demonstrated that IL-10 and TGF-β can directly 
inhibit human T cell proliferation through interruption of IL-2 and IFN-γ 
production (209, 210). However, addition of excess anti-IL-10 receptor blocking 
antibody (20 µg/ml, sufficient to block the effects of 10 ng/ml IL-10 activity) or 
anti-TGF-β antibody (10 µg/ml, sufficient to neutralize the effect of 10 ng/ml 
TGF-β) fails to abrogate the suppressive effect on CD4+ T cell proliferation. The 
lack of effects of the anti-IL-10 receptor blocking antibody and the TGF-β 
neutralizing antibody on the suppression of CD4+ T cell proliferation, may 
therefore indicate that neither IL-10 nor TGF-β are likely to be directly 
responsible for the inhibition of proliferation mediated by H69 SCLC cells. The 
next set of experiments focused on identification of novel soluble factors that 
can inhibit CD4+ T cell proliferation. In addition, although IL-10 and TGF-β are 
not involved in direct inhibition of T cell proliferation, they have been shown to 
induce CD4+CD25+ regulatory T (Treg) cells that supress activation and 
proliferation of effector T cells (193-195). Suppression of CD4+ T cell 
proliferation can result from expansion of Treg cells. It is therefore also 
important to address whether H69 cells suppress cell-mediated immune 
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4.1 Introduction  
 
In addition to effector immune cells, regulatory T cells are indispensable for the 
maintenance of dominant self tolerance and immune homeostasis (211). CD4+ 
regulatory T cells (Tregs) are characterized by functional ability to suppress the 
proliferation of conventional CD4+ T cells and by the expression of the cell 
surface marker CD25 and the intracellular marker (FoxP3) (212). Naturally 
occurring Tregs (nTregs), which are developed in thymus, comprise 5-10% of 
peripheral CD4+ T cells (213). They exert suppressive activity on effector T cells 
through a cell-to-cell contact dependent, IL-10 and TGF-β independent 
mechanism (214). Adaptively induced Tregs (iTregs) are induced from 
conventional CD4+ T cells in the periphery in a tolerogeneic environment.  The 
suppressive effect of iTregs is usually mediated by secreting large amounts of 
the potent immunosuppressive cytokines IL-10 and TGF-β (214). 
 
In the past years, immune therapies have been introduced as treatments for a 
variety of cancers (175). However, CD4+FoxP3+ Treg cells are believed to be 
one of immunosuppressive elements present in cancer patients that are critical 
impediments to the success of cancer immunotherapy (175, 176). Increased 
numbers of FoxP3+ Treg cells were first found in patients with NSCLC and 
ovarian cancer (215). Subsequently, a higher frequency of Tregs in peripheral 
blood has been reported in the patients with various cancers including NSCLC, 
ovarian cancer, breast cancer, gastric cancer, esophageal cancer, lymphoma, 
leukaemia, melanoma and pancreatic cancer (215-219). These FoxP3+ cells 
isolated from peripheral blood or solid tumours of patients have been shown to 
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have suppressive effects in vitro and may thus contribute to tumour growth (220, 
221). There are different compositions of FoxP3+ cell subpopulations with 
distinct phenotypes and functions present in tumour tissues (176, 222). 
Accumulation of suppressive FoxP3+ Treg cells can promote tumour cell growth 
and thus predict a poor prognosis, whilst non-suppressive FoxP3+ cells, which 
are capable of releasing pro-inflammatory cytokines, can activate anti-tumour 
immune responses and thus contribute to better survival in cancer patients 
(222). The role of Treg cells in cancer is not fully understood and differs with 
type of tumours. Therefore, determining the effects of Treg cells on initiation and 
progression of SCLC may help with the development of novel 
immunotherapeutic strategies.   
 
There are several potential sources for Treg cells in the tumour 
microenvironment. Treg cells express CC-chemokine receptor 4 (CCR4). 
Tumour cells and/or tumour infiltrating antigen-presenting cells (APCs) produce 
the CC-chemokine ligand 22 (CCL22), which can chemo-attract and recruit Treg 
cells in peripheral blood or lymph nodes to infiltrate into tumour sites (223). In 
addition, the tumour microenvironment contains factors such as VEGF, IL-10 
and TGF-β that suppress APC differentiation and function. Dysfunctional APCs 
can induce Treg cell differentiation and expansion (220). Furthermore, effector 
CD4+ T cells can be converted into Treg cells by the presence of high levels of 
IL-10 and TGF-β present in the tumour microenvironment (224, 225). Therefore, 
increased frequencies of FoxP3+ Treg cells that are found in the tumour 
microenvironment may contain recruited and expanded nTregs, and/or locally 
converted iTregs.  
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Phenotypic characterization of Tregs is difficult due to lack of specific markers. 
Under physiological conditions, CD25 is constitutive expressed on the cell 
surface of Tregs, but has poor specificity under conditions of immune activation. 
FoxP3 has been identified as a master transcriptional regulator in the 
development and suppressive function of Tregs, but there is increasing 
evidence showing that CD4+CD25- T cells become FoxP3-positive upon 
activation (226, 227).  CD127, the α-chain of the IL-7 receptor, has been shown 
to be a marker to discriminate between human CD4 regulatory and activated T 
cells, and its expression inversely correlates with FOXP3 and suppressive 
function (228, 229). Helios protein, a member of Ikaros transcription factor 
family, was first reported to distinguish between thymic-derived nTregs and 
peripherally induced iTregs (230). However, it is no longer a useful marker for 
identification of Treg cell phenotype. Helios is associated with T cell activation 
and proliferation (231), and it is selectively up-regulated in CD4+ T cells during 
differentiation of Th2 and follicular helper T (Tfh) cells responses in vivo 
independently of FoxP3 expression (232). It has been described that Helios is 
also expressed in peripherally induced FoxP3+ Tregs both in vitro and in vivo 
(233).  
 
In this chapter an in vitro co-culture of H69 SCLC cells with CD4+ T cells was 
established to explore the hypothesis that SCLC cells induce increased 
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4.2 Results 
 
4.2.1 SCLC cell-secreted soluble molecules induce 
CD4+CD25+CD127lowHelios-FoxP3+ Treg cells in a dose dependent fashion.  
 
The observed suppression of activated CD4+ T cell proliferation by H69 SCLC 
cells or H69 culture supernatant was associated with increased IL-10 
concentration in the supernatant (Chapter 3).  I therefore went on to investigate 
whether there were also alterations in Treg population that could result in both 
increased IL-10 secretion and the suppression of CD4+ T cell proliferation.   
 
Surface markers CD4 and CD25, and the intracellular marker FoxP3 were used 
to identify Tregs. Firstly, the frequency of CD4+CD25+FoxP3+ Tregs in peripheral 
blood was found to be 5.42 ± 0.22 % of total purified CD4+ T cells (Fig. 4.1A and 
4.1D). Above 98% of CD4+ T cells were activated in response to anti-CD3/CD28 
stimulation, and the cells were gated on CD25 expression (Fig. 4.1B).  
 
Co-culture of H69 SCLC cells in transwells with activated CD4+ T cells 
significantly induced the expansion of CD4+CD25+FoxP3+ Treg cells in a dose-
dependent fashion in comparison with activated CD4+ T cells cultured alone 
(Fig. 4.1B and 4.1D).  To further identify the phenotype of this increased Treg 
population, the cells were stained with anti-CD4, anti-CD25, anti-CD127, anti-
Helios and anti-FoxP3 antibodies, and were gated on CD4, CD25 and FoxP3 
expression. As shown, H69 SCLC cells-induced expansion of Treg cells had a 
phenotype of CD4+CD25+CD127lowHelios-FoxP3+ (Fig. 4.1C).   
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Similarly, the frequency of CD4+CD25+FoxP3+ cells was also significantly 
increased by culture with H69CM compared to CD4+ T cells cultured alone 
following activation (Fig. 4.1E). These data suggest that H69 SCLC cells 
constitutively produce soluble factors that induce the expansion of 
CD4+CD25+FoxP3+ Treg cells, and so suppress CD4+ T cell proliferation.  
 
 








Figure 4.1: Soluble molecules secreted by H69 SCLC cells induce FoxP3+ Treg cells in a dose 
dependent fashion. The experiments were performed as described in Chapter 2. (A) 
Representative flow cytometry data showing the percentages of ex vivo CD4+CD25+ and 
CD4+FoxP3+ cells from peripheral blood. (B) Representative flow cytometry data showing the 
populations of CD4+CD25+FoxP3+ cells. (C) Representative flow cytometry data showing the 
populations of CD4+CD25+CD127lowHelios-FoxP3+ cells. (D) The populations of 
CD4+CD25+FoxP3+ cells from ex vivo, activated CD4+ T cells cultured alone or co-cultured with 
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different ratios of H69 cells (mean ± SEM, n=6 experiments). ** Indicates p < 0.01 and *** p < 
0.0001. (E) The populations of CD4+CD25+FoxP3+ cells from activated CD4+ T cells cultured 
alone or with 40% of H69 SCLC CM (mean ± SEM, n=4 experiments). ** Indicates p < 0.01.  
 
 
4.2.2 H69 SCLC cells induce increased Treg population through the 
differentiation of naïve CD4+ T cells.  
 
It remains difficult to accurately distinguish iTregs from nTregs using current 
molecular markers. Both express the canonical Treg markers: CD25, FoxP3, 
CTLA-4 and GITR, although nTregs exhibit a higher expression of programmed 
cell death-1 (PD-1), CD73, neuropilin 1 (Nrp1) and Helios compared with iTreg 
(234), there is no consistent or reliable marker.  
 
To assess whether the increased population of FoxP3+ Tregs was due to 
expansion of pre-existing nTregs or induction from naïve T cells (iTregs), naïve 
CD4+ T cells were first purified. The purified naïve T cells had the phenotype of 
CD4+CD45RA+CD25-CD127HiFoxP3- (Fig. 4.2A), confirming the absence of pre-
existing nTregs. Subsequent co-culture of H69 SCLC cells with naïve CD4+ T 
cells significantly increased CD25+CD127lowFoxP3+ Treg cell population 
compared to naïve CD4+ T cells cultured alone in response to stimulation (Naïve 
CD4 only: 4.5%, Naïve CD4+H69: 16.6%, Fig.  4.2B). The result was highly 
similar to the increase in Treg population induced from a mixed population of 
CD4+ T cells by H69 SCLC cells (Fig. 4.1B, 4.1C and 4.1D). Furthermore, these 
H69 SCLC cell-induced FoxP3+ cells showed impaired proliferative ability (Fig. 
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4.2C). Together these data suggest that the increased FoxP3+ Treg cell 
population was derived from differentiation of naïve CD4+ T cells rather than by 
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Figure 4.2: SCLC-induced Treg cells are derived from differentiation of naïve CD4+ T cells. 
Representative flow cytometry showing (A) the populations of purified naïve 
CD4+CD45RA+FoxP3- cells (B) the populations of CD4+CD25+CD127lowFoxP3+ cells in the 
absence and presence of H69 cells  (C) the proliferations of FoxP3+ cells in the presence or 
absence of H69 cells.  
 
 
4.2.3: SCLC-induced Treg cells are functional to suppress effector CD4+ T 
cell proliferation.  
 
To determine whether the FoxP3+ Treg population induced from naïve CD4+ T 
cells can suppress the conventional CD4+ T cell proliferation, a Treg functional 
assay was established. The proliferation of naïve CD4+ T cells in response to 
stimulation was significantly suppressed by the presence of autologous CD4+ T 
cells previously co-cultured with H69 SCLC cells (Fig. 4.3A and 4.3B). The data 
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suggest that the FoxP3+ cells induced by H69 SCLC cells are indeed functional 
Treg cells capable of suppressing CD4+ T cell proliferation.  
 
To investigate whether the suppressive function of these induced Tregs is 
mediated by IL-10 or TGF-β secretion, anti-IL-10 receptor blocking antibody and 
TGF-β signalling inhibitor (SB431542) were used to block their functions. 
Blocking of IL-10 or TGF-β activities, or both together, failed to abrogate the 
suppressive effect on CD4+ T cell proliferation that was mediated by H69 SCLC 
cell-induced FoxP3+ cells (Fig. 4.3C and 4.3D). The data are consistent with 
observations for CD4+ T cells as a whole, suggesting that the suppressive effect 
of H69 SCLC cell-induced Treg cells is independent of IL-10 or TGF-β 
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Figure 4.3: SCLC-induced Treg cells are functional to suppress effector CD4+ T cell proliferation. 
The experiments were performed as described in section 2.17 Chapter 2. (A) Representative 
flow cytometry showing the total populations of dividing CD4+ T cells in the absence and 
presence of iTregs. (B) The total populations of dividing CD4+ T cells (mean ± SEM, n=4 
experiments). * Indicates p < 0.05. (C) Representative flow cytometry showing the total 
populations of dividing CD4+ T cells in the absence and presence of iTregs with or without the 
anti-IL-10 receptor antibody or the TGF-β signalling inhibitor (SB431542). (D) The populations of 




4.2.4 H69 but not H510 SCLC cells produce IL-15. 
 
The studies presented in Chapter 3 indicated that H69 but not H510 cells 
secreted small (<30kDa), heat-stable soluble factors capable of inhibiting CD4+ 
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T cell proliferation (Fig. 3.2B, 3,3B, 3.5A and 3.7). I therefore compared publicly 
available microarray data on H69 and H510 cells (GSE7068, Gene Expression 
Omnibus) to identify differentially expressed cytokine genes. Genes encoding 
IL-1α, IL-11, IL-15, IL-16, BMP-7, CSF-2 and TGF-β2 were identified as 
upregulated in H69 cells relative to H510 cells.  Of these TGF-β (193) and IL-15 
(235, 236) signalling have previously been described in relation to induction of 
Treg cells. TGF-β had no effect on suppression of CD4+ T cell proliferation in my 
experimental system (Fig. 3.11C). I therefore went on to study IL-15 as a 
candidate mediator of Treg cell induction.  
 
IL-15 levels were examined in H69 and H510 cell conditioned medium and cell 
lysates. IL-15 was detected in H69 cell culture supernatant at a low 
concentration (25.5 ± 3.7 pg/ml), but was below the detection limit (< 8 pg/ml) in 
H510 cell culture medium (Fig. 4.4A). H69 cell lysates contained much higher 
levels of IL-15 protein than those from H510 cells (Fig. 4.4A). Immunostaining 
on cytospins showed IL-15 was present in H69 but not in H510 cells (Fig. 4.4B). 
Importantly, malignant cells in tumour biopsies from SCLC patients contained 
large amounts of IL-15 (Fig. 4.4C). Addition of either recombinant IL-15 protein 
or IL-15 neutralizing antibody to H69 cell culture did not have effect on H69 
tumour cell growth (Fig. 4.4D).  
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Figure 4.4: H69 but not H510 SCLC cells produce IL-15. (A) IL-15 concentration in H69 and 
H510 CM and cell lysates assessed by ELISA (mean ± SEM n=4 experiments). *** Indicates p < 
0.0001. (B) Representative immunohistochemistry staining for IL-15 on H69 and H510 cell 
cytospins. (C) Representative immunohistochemistry staining for IL-15 on tumour biopsy 
sections from SCLC patients. Left panel: no IL-15 staining, middle panel: IL-15 staining under 
X100 magnification, right panel: IL-15 staining under X200 magnification. (D) Graph shows H69 
cell numbers at 24, 48 and 72 hours when cultured alone of in the presence of recombinant IL-
15 or anti-IL-15 neutralizing antibody (mean ± SEM, n=4 experiments). 
 
 
4.2.5 IL-15 is a factor in H69CM that induces Treg cell population.  
 
To investigate whether IL-15 induces Treg populations, recombinant IL-15 (rIL-
15) was added to naïve CD4+ T cells in response to stimulation.  Addition of 
recombinant rIL-15 protein significantly increased the population of 
CD4+CD25+FoxP3+ cells in a dose-dependent fashion compared to CD4+ T cells 
cultured alone (Fig. 4.5A and 4.5C). There was no difference in Treg cell 
induction between IL-15 protein at concentrations 20ng/ml and 200ng/ml (Fig. 
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4.5B). Interestingly, H69 cell conditioned medium (H69CM) induced significantly 
greater expansion of CD4+CD25+FoxP3+ cells in comparison with the effect of 
recombinant IL-15 (Fig. 4.5A and 4.5C). The data suggest that IL-15 is one but 
not the only soluble factor produced by H69 cells that can induce the 
differentiation of CD4+CD25+FoxP3+ Treg cells from naïve CD4+ T cells in 
response to activation. Alternatively, the rIL-15 used may be less active than 
endogenous IL-15 due to effects of purification process and/or post-translational 
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Figure 4.5: IL-15 is a factor in H69CM that induces Treg cell population. Representative flow 
cytometry showing the populations of CD4+CD25+FoxP3+ cells following incubation of anti-
CD3/CD28 stimulated CD4+ T cells with 20pg/ml or 20ng/ml rIL-15 or 40% H69CM (A) or 200ng 
rIL-15 (B). (C) The percentages of CD4+CD25+FoxP3+ cells from activated CD4+ T cells cultured 
alone, or with 20pg/ml or 20ng/ml rIL-15 protein, or with 40% H69CM (mean ± SEM, n=3 
experiments). * Indicates p < 0.05,  ** p < 0.01 and *** p < 0.0001.  
 
 
4.2.6 Addition of rIL-15 to H510CM has no additional effect on Treg cell 
induction.  
 
To investigate whether addition of IL-15 to H510 cell conditioned medium 
(H510CM) can have the same effect on Treg cell induction as H69 culture 
supernatant, recombinant IL-15 protein at the concentration of 20 pg/ml was 
added to CD4+ T cells in the presence of H510CM. Addition of IL-15 but not 
H510CM increased CD4+CD25+FoxP3+ Treg cell population compared to naïve 
CD4+ T cells cultured alone in response to activation (Fig. 4.6A and 4.6B). 
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Interestingly, the combination of IL-15 and H510CM did not induce greater Treg 
cell population compared to the effect of IL-15 alone on Treg cell induction (Fig. 
4.6A and 4.6B). Taken together these data suggest that H510CM has no 
additional synergistic or suppressive effect on induction of Treg cell population 
compared to IL-15 alone. This is in contrast to the observation that rIL-15 at 
concentrations found in H69CM had a lesser effect on Treg cell induction than 
H69CM itself. Therefore, there may be other soluble factors present in H69CM 
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Figure 4.6: H510CM does not affect Treg cell induction by rIL-15. (A) Representative flow 
cytometry showing the populations of CD4+CD25+FoxP3+ cells induced from naïve CD4+ T cells 
by rIL-15 alone and in combination with H510CM. (B) The percentages of CD4+CD25+FoxP3+ 
cells from activated CD4+ T cells cultured alone, or with 20pg/ml rIL-15, or with 40% H510CM, or 
with rIL-15 and H510CM (mean ± SEM, n=4 experiments). * Indicates p < 0.05.  
 
 
4.2.7 Blocking IL-15 reduces H69 SCLC cells-induced Treg cell 
differentiation and IL-10 secretion.  
 
To investigate the effect of blocking IL-15 on Treg cell population and IL-10 
secretion induced by H69 cells, IL-15 neutralizing antibody was used. There was 
no difference in Treg cell population between CD4+ T cells cultured alone and 
cultured with IL-15 neutralizing antibody (Fig. 4.7A and 4.7B).  The population of 
CD4+CD25+FoxP3+ cells was significantly increased by co-culture with H69 
SCLC culture medium in the presence of isotype control antibody. However, 
addition of IL-15 neutralizing antibody significantly reduced the expansion of 
Treg cells that was induced by H69CM in the presence of isotype control 
antibody (Fig. 4.7A and 4.7B). Interestingly, neutralization of IL-15 in H69CM 
failed to completely abrogate Treg induction compared to CD4+ T cell cultured 
alone (Fig. 4.7A and 4.7B). The data suggest that inhibition of IL-15 activity 
partially blocks the Treg cell differentiation that is induced by H69 SCLC cells.  
This further supports the hypothesis that IL-15 is only one of the secreted 
factors responsible for iTreg induction in this SCLC model.  
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Similarly, IL-10 secretion was significantly reduced by addition of IL-15 
neutralizing antibody to H69CM relative to isotype control antibody in this 
system (Fig. 4.7C). IL-10 production from activated CD4+ T cells cultured with 
H69CM in the presence of IL-15 neutralizing antibody remained significantly 
higher than activated CD4+ T cells cultured alone.  The data suggest that 
blocking IL-15 activity partially reduces H69 SCLC cell-induced IL-10 secretion 
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Figure 4.7: Blocking IL-15 activity reduces H69 SCLC cells-induced Treg cell differentiation and 
IL-10 secretion. (A) Representative flow cytometry showing the populations of 
CD4+CD25+FoxP3+ cells following incubation of anti-CD3/CD28 stimulated naïve CD4+ T 
cultured alone, or with IL-15 neutralizing antibody (α-IL-15), or with H69CM plus isotype control 
antibody or with H69CM plus α-IL-15. (B) The percentages of CD4+CD25+FoxP3+ cells (mean ± 
SEM, n=4 experiments). *** Indicates p < 0.0001. (C) The concentration of IL-10 released from 
CD4+ T cells in the supernatants (mean ± SEM, n=6 experiments). ** Indicates p < 0.01 and *** 




4.2.8 Blocking of IL-15 activity partially reverses H69 SCLC cell-induced 
inhibition of MLR and CD4+ T cell proliferation.  
 
To investigate whether the suppression of MLR mediated by H69 SCLC cells 
can be reversed by blocking IL-15 activity, IL-15 neutralizing antibody was 
added. The 3H-thymidine uptake in MLR was not affected by the addition of IL-
	   122	  
15 neutralizing antibody, but was significantly reduced by co-culture with H69 
cells in the presence of isotype control antibody (Fig. 4.8A). Neutralization of IL-
15 significantly reversed the suppression of MLR mediated by H69 cells (Fig. 
4.8A). The percentage of MLR proliferation was suppressed to 63.8 ± 3.5% by 
co-culture with H69 cells, but was significantly increased to 76 ± 2.4% by 
neutralization of IL-15 (Fig. 4.8B). The data suggest that blocking of IL-15 
activity partially reverses the inhibition of MLR proliferation.  
  
Similarly, the suppression of activated CD4+ T cell proliferation in the presence 
of H69CM was significantly reversed by addition of IL-15 neutralizing antibody 
compared to isotype control antibody (Fig. 4.8C). The percentage of CD4+ T cell 
proliferation was suppressed to 66.2 ± 1.7% by H69CM, but was significantly 
increased to 83.6 ± 3.1% by neutralization of IL-15 (Fig. 4.8D). The data suggest 
that blocking of IL-15 activity can partially reverse H69 SCLC cell-induced 
suppression of CD4+ T cell proliferation. The magnitudes of these effects are 
similar to the observed above for partial blockade of H69 SCLC cell-induced 
Treg cell differentiation as a consequence of IL-15 neutralization.  
 
To investigate whether blocking of IL-15, IL-10 and TGF-β activities together can 
completely abrogate the suppressive effect of H69CM, IL-15 neutralizing 
antibody, IL-10 receptor blocking antibody and TGF-β receptors inhibitor were 
added to activated CD4+ T cell culture. There was no difference in H69CM-
induced inhibition of CD4+ T cell proliferation between IL-15 neutralizing 
antibody added alone and all the three antibodies combined together (Fig. 
4.8E). The suppressed CD4+ T cell proliferation was significantly reversed in the 
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presence of IL-15 neutralizing antibody, but a net inhibitory effect remained 
compared to activated CD4+ T cells cultured alone (Fig. 4.8E).  
 
To ensure the maximum neutralising effect has been achieved, IL-15 
neutralizing antibody was next pre-incubated with H69 cells prior to adding 
H69CM to CD4+ T cell culture. The percentage of proliferating CD4+ T cells in 
response to activation was significantly reduced by H69CM that was pre-
incubated with isotype control antibody (Fig. 4.8F and 4.8G). Pre-incubation of 
H69 cells in the presence of IL-15 neutralizing antibody significantly increased 
the percentage of CD4+ T cell proliferation, but remained statistically reduced 
compared to activated CD4+ T cells cultured alone (Fig. 4.8F, 4.8G and 4.8H). 
The data suggest that neutralization of IL-15 does not fully abrogate the 
suppressive effect on CD4+ T cell proliferation that is mediated by soluble 
factors secreted by H69 SCLC cells.  This is consistent with the observed 
results above that blocking of IL-15 activity can partially reverse H69 SCLC cell-
induced suppression of CD4+ T cell proliferation.  Taken together the data 
indicate that IL-15 is an important member of a set of soluble factors produced 
by H69 SCLC cells to suppress immune responses through induction of 
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Figure 4.8: Blocking of IL-15 activity partially reverses H69 SCLC cell-induced inhibition of MLR 
and CD4+ T cell proliferation. The experiments were performed as described in Chapter 2. (A) 
3H-thymidine uptake by MLR alone or with α-IL-15 antibody or isotype control in the absence 
and presence of H69 SCLC cells (mean ± SEM, n=5 experiments). * Indicates p < 0.05 and ** p 
< 0.01. (B) The percentages of MLR proliferation when co-cultured with H69 cells plus α-IL-15 
antibody or isotype control relative to MLR cultured alone. Each line represents an individual 
donor.  (C) 3H-thymidine uptake by CD4+ T cells alone or with α-IL-15 antibody or isotype control 
in the absence and presence of H69CM (mean ± SEM, n=8 experiments).   ** Indicates p < 0.01 
and *** p < 0.0001. (D) The percentages of CD4+ T cell proliferation when cultured with H69CM 
plus α-IL-15 antibody or isotype control relative CD4+ T cells cultured alone. Each line 
represents an individual donor.  (E) 3H-thymidine uptake by CD4+ T cells alone, or with H69CM, 
or with H69CM in the presence of α-IL-15 or in combination of α-IL-15, α-IL-10 and α-TGF-β 
(mean ± SEM, n=3 experiments). * Indicates p < 0.05 and ** p < 0.01. (F) Representative flow 
cytometry showing the total populations of dividing CD4+ T cells alone or in the absence and 
presence of H69CM pre-incubated with α-IL-15 or isotype control. (G) The total populations of 
dividing CD4+ T cells (mean ± SEM, n=3 experiments). * Indicates p < 0.05,  ** p < 0.01 and *** 
p < 0.0001. (H) The percentages of CD4+ T cell proliferation when cultured with H69CM plus α-
IL-15 antibody or isotyoe control relative to CD4+ T cells cultured alone. Each line represents an 
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4.3 Discussion  
 
The data presented in this chapter demonstrate that H69 SCLC cells produce 
IL-15 to induce a functional Treg cell population and thereby suppress effector 
CD4+ T cell proliferation in response to TcR and co-stimulatory molecule 
activation. This may represent an important mechanism by which SCLC cells 
suppress immune responses.  
 
The increased population of Treg cells have a phenotype of 
CD4+CD25+CD127lowHelios-FoxP3+. These cells are likely adaptively induced 
Treg cells as treatment of naïve CD4+ T cells with H69CM recapitulated the 
population similarly to the effect of the same treatment upon all CD4+ T cells. 
Currently, the functional study of human Treg cell-mediated suppressive activity 
is limited to in vitro co-culture assays, most of which measure thymidine uptake 
by cultured T cells in the presence or absence of Tregs. In this chapter, a novel 
Treg functional assay is established by co-culture of CFSE-labelled naive CD4+ 
T cells with unlabelled autologous CD4+ T cells previously co-cultured with H69 
SCLC cells in the presence of CD3/CD28 stimulation. The induced FoxP3+ cells 
demonstrate low levels of proliferation but are functional in suppressing the 
percentage and number of proliferating effector CD4+ T cells. The results are 
highly consistent with other data from studies of mouse and human Treg cells. 
These are consistently hypoproliferative in vitro but can effectively inhibit 
polyclonal T cell activation and proliferation responses to stimulation (237, 238).  
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The precise molecular mechanisms by which regulatory T cells suppress CD4+ 
T cell proliferation in humans remain to be determined, although they have been 
extensively studied in mouse and cell models (211). Both human and murine 
Treg cells may suppress effector cells through physical elimination by direct cell-
to-cell contact, the production of suppressive cytokines and the consumption of 
cytokines and growth factors (239). However, some of the suppressive 
mechanisms employed by murine Treg cells have not been described in 
humans (240). Furthermore, there is no direct evidence showing that 
suppressive mechanisms identified in vitro directly reflect in vivo suppressive 
capacities of Treg cells (211). Human Treg cells must be activated through their 
TcR to be functionally suppressive (241, 242). Once activated, Tregs can exert 
suppressive effects on a variety of immune cells including effector CD4+, CD8+ T 
cells, B cells, NK cells, NKT cells, monocytes, macrophages and dendritic cells 
(DCs). These may be mediated by cell contact and/or soluble factors (211).  
 
Treg cells induced by co-culture of CD4+ T cells with H69 SCLC cells directly 
suppress effector CD4+ T cell proliferation. The result supports the previous 
findings that human Treg cells can be suppressive in vitro even in the absence 
of APCs (243, 244). IL-2 consumption by Treg cells can reduce T cell 
proliferation and induce apoptosis of effector CD4+ T cells (245, 246). The data 
in Chapter 3 demonstrate that the CD4+ T cell proliferation suppressed by co-
culture with H69 cells is not associated with reduction in IL-2 secretion. It may 
suggest that IL-2 is not required for SCLC cell-induced Treg cell suppressive 
function, which has been reported by other studies (247, 248).  
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Induced Treg (iTreg) cells have to date be considered to mediate their 
suppressive activity through the effects of secreting the immunosuppressive 
cytokines TGF-β and IL-10 (214). The data here indicate that SCLC cell-induced 
FoxP3+ cells are likely adaptively induced iTreg cells (Fig. 4.2). However, 
surprisingly, the suppression of CD4+ T cell proliferation by these iTreg cells is 
not mediated through IL-10 or TGF-β (Fig. 4.3). Although unlikely, the anti-IL-10 
receptor blocking antibody or anti- TGF-β neutralizing antibody/TGF-β signalling 
inhibitor may not actually be working, future experiments for positive controls 
need to be performed to exclude this possibility. Previous studies have 
demonstrated that Treg cells can produce membrane-bound and soluble TGF-β, 
and that suppression of T cell proliferation can be partially abrogated by 
blocking TGF-β (249, 250). However, no active TGF-β is detected in the co-
culture of H69 SCLC cells with activated CD4+ T cells, and blocking TGF-β fails 
to reverse the suppression of CD4+ T cell proliferation in response to 
stimulation. The data suggest the suppressive effect of SCLC cell-induced Tregs 
is independent of TGF-β, which is similar to other groups’ results demonstrating 
that TGF-β is not involved in Treg-mediated suppression (251, 252). Similarly, 
whilst IL-10 secretion from activated CD4+ T cells is significantly increased by 
co-culture with H69 SCLC cells, blocking IL-10 activity fails to abrogate the 
suppressive effect of induced Treg cells. Therefore, the effect of IL-10 in the 
SCLC tumour microenvironment may be involved in Treg cell induction and 
maintenance rather than direct suppressive effect on T cells. This is supported 
by recent studies demonstrating that IL-10 indirectly influences suppression of 
CD4+ T cell proliferation by acting on Tregs to maintain FoxP3 expression and 
suppressive function (253). SCLC cell-induced FoxP3+ cells may therefore 
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represent a novel subset of iTreg cells. These may be different from iTreg cells 
that have been previously described and use other mechanisms to suppress 
CD4+ T cell proliferation (239).  
IL-15 is a member of the family of IL-2 cytokines with a molecular weight of 
~14kDa. The IL-15 receptor is a heterotrimeric receptor composed of three 
subunits, (IL-15R) α and β, and the common cytokine receptor γ-chain (γc) 
(254). IL-15Rα is specific for the IL-15 receptor whilst IL-15Rβ (CD122) is 
shared with the receptor for IL-2, and γc (CD132) is shared with receptors for IL-
2, IL-7, IL-4, IL-9 and IL-21. IL-15 is constitutively expressed by a large number 
of cells including monocytes, macrophages, dendritic cells, lymphocytes, 
fibroblasts, epithelial and stromal cells (254). The expression of IL-15 and the 
number of IL-15+ cells in healthy normal lung tissue are limited, but increase 
significantly in inflammatory pulmonary diseases (255). The data in this chapter 
demonstrate that H69 SCLC cells but not H510 produce IL-15, and malignant 
cells in tumour biopsies from SCLC patients stain strongly positive for IL-15. The 
data are consistent with an early study demonstrating that some but not all 
SCLC cell lines display IL-15 gene expression (256). H69 cell growth is not 
affected by addition of either recombinant IL-15 protein or blocking IL-15 activity 
with a neutralizing antibody.  
 
The data demonstrate that IL-15 induces an increased population of functional 
FoxP3+ Treg cells, and these are responsible for the suppression of the CD4+ T 
cell proliferative response to activation. The data suggest that IL-15 may have 
these effects by promoting iTreg cell population to suppress immune response 
in SCLC. This is consistent with other reports showing that IL-15 can induce 
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population of FoxP3+ regulatory T cells (235, 257-260). Similar to the data 
presented here, IL-15 has been shown to increase CD25 and FoxP3 expression 
on CD4+ T cells to induce Treg cells (235). Furthermore, the presence of IL-15 is 
required for Treg cell expansion and genetic depletion or neutralization of IL-15 
reduces Treg cell population (257-260). Interestingly, neutralization of IL-15 
partially blocks induction of Treg cells and IL-10 secretion, and abrogates the 
suppressed MLR and CD4+ T cell proliferation mediated by H69 SCLC cells. 
The lack of complete reversal of IL-15-mediated effects is not due to insufficient 
dose or incubation time of the neutralizing antibody. In the experiments 
described in this chapter, IL-15 neutralizing antibody was added at high molar 
excess (200ng/ml), sufficient to neutralize a far higher IL-15 concentration 
(1ng/ml) than detected in H69 conditioned culture medium. In addition, pre-
incubation of IL-15 neutralizing antibody with H69 culture supernatant shows a 
similar suppressive effect on CD4+ T cell proliferation as the simultaneous 
incubation. The data suggest that IL-15 is one, but not the only, soluble 
molecule produced by H69 cells to mediate immune suppression by inducing 
increased population of Treg cells. Analysis of microarray data shows that in 
addition to IL-15, IL-1α, IL-11, IL-16, BMP-7 and CSF-2 genes are up-regulated 
in H69 cells relative to H510 cells. Future experiments may therefore usefully 
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Chapter 5: Small Cell Lung Cancer Cells Produce 
Bombesin-like Peptides (BLPs) to Regulate the 
Phenotype and Function of Monocytes and Monocyte-
















	   133	  
Chapter 5 Small Cell Lung Cancer Cells Produce Bombesin-like Peptides 
(BLPs) to Regulate the Phenotype and Function of Monocytes and 
Monocyte-Derived Macrophages (MDMs). 
5.1 Introduction..................................................................................134  
5.2 Results.........................................................................................138 
5.2.1 SCLC cells and tumour biopsies express  
         gastrin-releasing peptide receptor (GRP-R).......................138  
5.2.2 RC-3095, a GRP-R antagonist, inhibits the  
         growth of SCLC cells in vitro...............................................139 
5.2.3 Blocking bombesin/GRP signalling has no  
         effect on H69CM-induced suppression of  
         CD4+ T cell proliferation......................................................141  
5.2.4 Blocking bombesin/GRP signalling reverses  
         H69 cell-induced suppression of MLR proliferation............143  
5.2.5 H69 SCLC cells up-regulate GRP-R expression  
         on monocytes and monocyte-derived  macrophages   
         (MDMs)...............................................................................144  
5.2.6 BLPs suppress LPS-induced activation of monocytes.......146  
5.2.7 BLPs can induce alternatively activated macrophage   
         phenotype...........................................................................149 
5.2.8 BLP suppress TNF-α and IL-6 production,  
         and increases IL-10 secretion from activated MDMs.........154  
5.3 Discussion...................................................................................158  
 
 
	   134	  
5.1 Introduction 
 
Bombesin-like peptides (BLPs) are neuropeptides that include bombesin, 
gastrin-releasing peptide (GRP) and neuromedin (NMB) (Table 5.1) (56). 
Bombesin and GRP share a conserved bioactive C-terminal heptapeptide 
sequence that underlies their similar specificities for GRP receptor (GRP-R) and 
similar physiological effects (57). BLPs have been shown to have mitogenic 
activity in a large variety of human cancers (261). SCLC cells produce BLPs and 
GRP that function as autocrine and paracrine growth factors to promote tumour 
growth and invasion (103).   It is well established that many SCLC cells produce 
both bombesin and GRP at significant concentrations, and GRP mRNA has 
been detected in H69, H345 and H510 SCLC cell lines (262, 263).  
 
Table 5.1: Bombesin-like peptides (BLPs)  
 
 
There are three subtypes of BLP receptors expressed in mammalian tissues: 
GRP receptor (GRP-R), NMB receptor (NMB-R) and bombesin receptor subtype 
3 (BB3) (56). GRP-R has high affinity for bombesin and GRP and very low 
affinity for NMB. GRP-R is expressed by the majority of SCLC cell lines 
characterized to date and is much more commonly found in human 
malignancies than in normal human tissues (264-266). The production of GRP 
together with overexpression of GRP-R by tumour cells results in autocrine 
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growth stimulation and correlates with poor prognosis (267). Moreover, blocking 
BLPs or GRP-R with neutralizing antibodies or receptor antagonists significantly 
inhibits SCLC tumour growth both in vivo and in vitro (64, 268).  
 
BLPs have been shown to affect immune cell function modulating lymphocyte 
proliferation and antigen presenting cell capability. Early studies have 
demonstrated that GRP and bombesin can suppress the proliferation of murine 
lymphocytes in response to activation (269, 270). Lung cancer-derived BLPs 
including GRP have been shown to inhibit human dendritic cell (DC) maturation 
and inhibit IL-12 production by DC and T cell activation (271). Furthermore, 
these neuropeptides are chemoattractants for human monocytes and 
macrophages and can induce macrophage phagocytosis and activation (272-
274).  
 
Macrophages play an indispensable role in the immune system with decisive 
functions in both innate and adaptive immune response. However, their 
presence within the tumour microenvironment has been associated with 
enhanced tumour initiation and progression, promoting cancer cell growth and 
metastasis, angiogenesis and immunosuppression (145). Two different classes 
of macrophages (denoted M1 and M2) have been described.  These can exert 
diverse functions depending on the different origins, local environment and 
responses to challenges (143, 275). Macrophage types in vivo and in disease 
are likely phenotypically more complex than simple M1/M2 types (276). 
Nevertheless, these models may aid useful discrimination between different 
types of macrophages behaviour (275). Classically activated (M1) macrophages 
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are characterized by high antigen-presenting capacity, pro-inflammatory 
cytokine secretion and production of nitric oxide (NO). They are potent effector 
immune cells that are capable of killing pathogens and tumour cells (143).  
Alternatively activated (M2) macrophages are characterized by high 
phagocytosis capacity and anti-inflammatory cytokine production. They are 
associated with angiogenesis, wound healing, tissue repair and 
immunosuppression (143, 275).   
 
In cancer, tumour-associated macrophages (TAMs) appear to play permissive 
role in disease. Activated macrophages play roles in early tumour pathogenesis, 
releasing high levels of pro-inflammatory cytokines to sustain the chronic 
inflammation that seems to be causal in tumour initiation and promotion (277). 
M1 macrophages secrete TNF-α, IL-6 and IL-1 that are the most common pro-
inflammatory cytokines in the tumour microenvironment, therefore, these TAMs 
may display M1-like phenotype. Once tumours are established, these TAMs 
may change from an immunologically active state (M1-like) to adopt a 
protumoral, immunosuppressive (M2-like) phenotype (145). TAMs isolated from 
established tumours generally display an M2-like phenotype. These TAMs have 
an IL-2lowIL-10hi phenotype, show less antigen presenting and tumoricidal 
capacity, enhanced phagocytic capacity and high expression of angiogenic 
factors (278, 279). In contrast to M1 macrophages, TAMs produce less nitric 
oxide and reactive oxygen intermediates, and express low levels of 
inflammatory cytokines, and thus may represent a skewed M2 population (280, 
281). It has been shown that in NSCLC, macrophages polarize to an M2-like 
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protumoral phenotype during tumour formation, with suppressive effects on T 
cell responses (282, 283).  
 
I hypothesised that the observed suppressive effects on CD4+ T cells and MLR 
could be mediated by SCLC cell-derived BLPs. To assess this, I characterised 
the expression of GRP-R on SCLC cell lines and tumour biopsies, and the effect 
of blocking BLP signalling on tumour cell growth. I also wished to study whether 
BLP signalling could affect polarization of monocyte-derived macrophages 
(MDMs). To this end, in vitro co-cultures of H69 cells with MLR and CD4+ T cells 
in the absence or presence of a GRP-R antagonist were established 
respectively. The aim was to investigate whether SCLC cell-derived BLP could 
supress proliferation of MLR and CD4+ T cells. In addition, in vitro co-cultures of 
H69 cells with monocytes and MDMs in the absence or presence of a GRP-R 
antagonist were established respectively. The aim was to explore the hypothesis 
that SCLC cell-derived BLPs may regulate the phenotype and functions of 
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5.2 Results 
 
5.2.1 SCLC cells and tumour biopsies express gastrin-releasing peptide 
receptor (GRP-R).  
 
SCLC cells secrete various neuroendocrine growth factors including BLPs and 
GRP, and their receptors are also widely expressed by SCLC cell lines leading 
to the development of autocrine and paracrine growth stimulatory loops (101, 
102). To investigate whether H69, H345 and H510 SCLC cells express GRP 
receptor (GRP-R), cell lysates were probed for GRP-R by western blot analysis 
of SDS-PAGE. GRP-R was expressed in all three SCLC cell lines at different 
levels with highest expression in H69 cells, intermediate expression in H345 
cells and lowest expression in H510 cells (Fig. 5.1A). Immunohistochemistry 
staining showed that GRP-R was expressed on primary tumour biopsies from 
SCLC patients (Fig. 5.1B).  
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Figure 5.1: SCLC cells and tumour biopsies express GRP-R.  (A) Representative western blot 
for GRP-R in H69, H345 and H510 SCLC cells (n=4 independent experiment). (B) 
Representative IHC staining for GRP-R in formalin-fixed, paraffin-embedded SCLC tumour 
sections. Left panel shows unstained tumour biopsy with the anti-GRP-R antibody Right panel 




5.2.2 RC-3095, a GRP-R antagonist, inhibits the growth of SCLC cells in 
vitro.  
 
Synthetic human GRP-R antagonists bind with high affinity and block the 
receptor-activated signal transduction pathways. To investigate whether 
blocking GRP activity can affect SCLC tumour cell growth in vitro, RC-3095 (D-
TPI6, LEU13 y(CH2-NH)-LEU14)BOMBESIN (6-14), a potent GRP-R antagonist 
was added to SCLC cell culture. H69, H345 and H510 cells were cultured alone, 
or with DMSO (5µl), or with RC-3095 in DMSO at concentrations of 1µM, 5µM 
and 10µM. Cell viability was assessed by MTT assay at 72 hours. There were 
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no differences in cell viability between SCLC cells (H69, H345 and H510) 
cultured alone or with DMSO (Fig. 5.2A). Addition of RC-3095 at the 
concentration of 1µM did not affect H69, H345 or H510 cell viability compared to 
the cells cultured alone (Fig. 5.2A). However, culture with RC-3095 at higher 
concentrations (5µM and 10µM) significantly reduced the viability of all the three 
SCLC cell lines (Fig. 5.2A). The data suggest that blocking bombesin/GRP 
signalling can inhibit SCLC cell growth in vitro.  
 
The phosphoinositide 3-kinase (PI3K/Akt) signalling pathway has been shown to 
deliver an anti-apoptotic signal to promote cell survival and its dysregulation is 
implicated in various human cancers (284). To assess whether this pathway is 
involved in the suppressive effect of RC-3095 on the cell viability of SCLC cells, 
cell lysates were probed for phospho-Akt (P-Akt) and Akt. As shown, 
phosphorylation of Akt in H69, H345 and H510 cells was significantly inhibited 
by the addition of 5µM and 10µM RC-3095 to the cell culture (Fig. 5.2B). The 
data correlate well with the observed effects of 5µM and 10µM RC-3095 on 
SCLC cell viability, supporting the hypothesis that treatment with the higher 
doses of GRP-R antagonist may inhibit SCLC tumour cell growth in vitro via the 





	   141	  
 
 
Figure 5.2: RC-3095, a GRP-R antagonist, inhibits the growth of SCLC cells in vitro. H69, H345 
and H510 cells per well cultured alone, or with DMSO, or with RC-3095 (1µM, 5µM and 10µM) in 
24-well plates. Cell viability was assessed by MTT assay at 72 hours. (A) Graph shows the MTT 
absorbance (mean ± SEM, n=5 experiments). ** Indicates p < 0.01 and *** p < 0.0001. (B) 
Representative SDS-PAGE western blot analysis of H69, H345 and H510 cell lysates with 




5.2.3 Blocking bombesin/GRP signalling has no effect on H69CM-induced 
suppression of CD4+ T cell proliferation.  
 
BLPs have been shown to suppress proliferation of murine lymphocytes (270). 
To investigate whether blocking bombesin/GRP signalling could abrogate the 
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suppression of CD4+ T cell proliferation mediated by H69 conditioned medium 
(H69CM), RC-3095 was pre-incubated with H69 cells prior to adding H69CM to 
CD4+ T cell culture. RC-3095 was used at concentration of 1 µM since this 
concentration has no effect on H69 cell viability (Fig. 5.2). CD4+ T cell 
proliferation was not affected by addition of RC-3095 compared to the cells 
cultured alone, but was significantly reduced by H69CM in the presence of 
DMSO (Fig. 5.3A and 5.3B). However, addition of RC-3095 failed to abrogate 
the H69CM-suppressed CD4+ T cell proliferation compared to DMSO control 
(Fig. 5.3A and 5.3B). Blocking of IL-15 activity significantly reversed the 
suppression of CD4+ T cell proliferation, but combination of RC-3095 had no 
additional effect on this (Fig. 5.3A and 5.3B). Lack of effect of RC-3095 
antagonist on the suppression of T cell proliferation may suggest that 
bombesin/GRP signalling does not mediate the suppression of CD4+ T cell 
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Figure 5.3: Blocking BLP signalling has no effect on H69CM-induced suppression of CD4+ T cell 
proliferation.  (A) 3H-thymidine uptake by CD4+ T cells following activation culture alone or with 
RC-3095 (1µM), or with 40% H69 CM in the presence of DMSO or RC-3095, or anti-IL-15, or 
RC-3095 plus anti-IL-15  (mean ± SEM n=4 experiments). * Indicates p < 0.05 and ** p < 0.01. 
(B) The percentage of CD4+ T cell proliferation when cultured with H69CM and different 
additives relative to CD4+ T cells cultured alone or with RC-3095 (n=4 experiments). Each line 




5.2.4 Blocking bombesin/GRP signalling reverses H69 cell-induced 
suppression of MLR proliferation.  
 
I next wished to investigate whether bombesin/GRP signalling mediates the 
suppressive effects of H69 cells upon proliferation in the MLR. To this end, 1µM 
RC-3095 was added to MLR culture system. GRP-R blockade had no significant 
direct effect upon proliferation in the MLR, whilst co-culture with H69 cells in the 
presence of DMSO control demonstrated the suppressive effect of this SCLC 
cell line  (Fig. 5.4A and 5.4B). Interestingly, this effect was significantly reversed 
by the addition of RC-3095.  Neutralization of IL-15 also reversed the 
suppressed MLR proliferation, but remained significantly (p <0.05) reduced 
compared to MLR cultured alone (Fig. 5.4A and 5.4B). However, the 
combination of RC-3095 and anti-IL-15 fully abrogated the suppressive effect on 
MLR mediated by H69 cells (Fig. 5.4A and 5.4B). Together the data suggest 
that bombesin/GRP signalling, in addition to IL-15 signalling, mediates the 
suppression of MLR proliferation caused by H69 cells.  
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Figure 5.4: Blocking BLP signalling reverses H69-induced suppression of MLR proliferation. (A) 
Graph represents 3H-thymidine uptake by MLR cultured alone, or with RC-3095 (1µM), or co-
cultured with mitomycin C treated H69 cells in the presence of DMSO, or RC-3095, or anti-IL-15, 
or RC plus anti-IL-15 (mean ± SEM, n=5 experiments). * Indicates p < 0.05 and ** p < 0.01. (B) 
Graph shows the percentage of MLR proliferation with different treatments compared to MLR 
cultured alone or with RC-3095 (n=5 experiments). Each line represents an individual donor. * 
Indicates p < 0.05.  
 
 
5.2.5 H69 SCLC cells up-regulate GRP-R expression on monocytes and 
monocyte-derived macrophages (MDMs)  
 
Blocking bombesin/GRP signalling had no effect on H69 SCLC cell-mediated 
suppression of CD4+ T cell proliferation (Fig. 5.3), but significantly abrogated the 
inhibition of MLR proliferation (Fig. 5.4). The data suggest that BLPs released by 
H69 cells might act on other cell types within PBMC population to suppress 
activation or proliferation of other immune cells. Therefore, I next wished to 
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determine whether BLPs may have effects on monocytes and monocyte-derived 
macrophages (MDMs). CD14+ monocytes were isolated and purified to >93% 
homogeneity, and were differentiated into MDMs displaying a characteristic 
phenotype of CD16+CD68+ (Fig. 5.5A). Both monocytes and MDMs expressed 
GRP-R and its expression was significantly up-regulated by co-culture with H69 
SCLC cells (Fig. 5.5B).  The data suggest that H69 cell-derived BLPs may 




Figure 5.5: H69 SCLC cells up-regulate the expression of GRP-R on monocytes and 
monocytes-derived macrophages. (A) Representative flow cytometry shows the isolation of 
PBMCs from peripheral blood, purification of CD14+ monocytes and differentiation of 
CD16+CD68+ MDM from monocytes. (B) Representative SDS-PAGE western blot probing for 
GRP-R in cell lysates (n=3 independent experiment).  
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5.2.6 BLPs suppress LPS-induced activation of monocytes.  
 
To investigate whether H69 SCLC cells can inhibit monocyte activation, H69 
cells were co-cultured with CD14+ monocytes. LPS was added as a pro-
inflammatory stimulus and TNF-α release was measured as a product of 
monocyte activation. H69 cells cultured alone or with LPS did not produce TNF-
α in the supernatant. TNF-α secretion was low when monocytes were cultured 
alone without stimulation, but was significantly increased in the presence of LPS 
(Fig. 5.6A). Interestingly, TNF-α production from LPS-stimulated monocytes was 
significantly reduced by co-culture with H69 cells (Fig. 5.6A). To determine 
whether the suppressive effect on TNF-α secretion was dependent on formation 
of cell contacts, transwells were used to separate the cells. TNF-α production 
from activated monocytes was significantly reduced by co-culture with H69 cells 
in a dose-dependent fashion (Fig. 5.6B). To investigate whether H69 culture 
supernatant can also have the inhibitory effect on monocyte activation, H69 
conditioned medium (H69CM) or PBS were added. There was no difference in 
TNF-α secretion between monocytes cultured alone or with addition of PBS. 
However, it was significantly reduced in the presence of H69 culture supernatant 
(Fig. 5.6C).  Together the data suggest that H69 SCLC cells produce soluble 
factors that are capable of suppressing TNF-α secretion from LPS-stimulated 
monocytes.  
 
To determine whether blocking bombesin/GRP signalling could reverse the 
suppressive effect of H69 cells on TNF-α secretion by LPS-stimulated 
monocytes, the effects of 1µM RC-3095 were assessed. Addition of DMSO or 
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RC-3095 did not affect the viability of LPS-stimulated monocytes cultured alone 
or in co-culture with H69 cells (Fig. 5.6D). TNF-α production was not affected by 
addition of DMSO or RC-3095 to LPS-stimulated monocytes, but was 
significantly reduced by co-culture with H69 SCLC cells alone or in the presence 
of DMSO (Fig. 5.6E). Interestingly, the suppression of TNF-α secretion was 
significantly reversed by addition of RC-3095, and the suppressive effect was 
abrogated compared to monocytes cultured alone (Fig. 5.6E). The data suggest 
that H69-derived BLPs may suppress activation of LPS-stimulated monocytes 
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Figure 5.6: BLPs suppress LPS-induced activation of monocytes. The experiments were 
performed as described in sections 2.6 and 2.12 Chapter 2.   (A) TNF-α concentration in culture 
supernatant from H69 cells cultured alone or with LPS, or monocytes cultured alone or with LPS 
in the absence or presence of H69 cells assessed by ELISA. (Mean ± SEM, n=4 experiments). 
*** Indicates p < 0.0001. (B) TNF-α concentration in culture supernatant from monocytes 
cultured alone or with H69 cells in the presence of LPS assessed by ELISA. (Mean ± SEM, n=3 
experiments). * Indicates p < 0.05,  ** p < 0.01 and *** p < 0.0001. (C) TNF-α concentration in 
culture supernatant from monocytes cultured alone or with 40% H69CM or PBS in the presence 
of LPS (Mean ± SEM, n=4 experiments). * Indicates p < 0.05. (D) Graph shows the cell viability 
by monocytes following activation with LPS, cultured alone or with H69 cells in the presence of 
DMSO or RC-3095 assessed by MTT assay (Mean ± SEM, n=3 experiments). (E) Graph shows 
TNF-α concentration (Mean ± SEM, n=3 experiments). * Indicates p < 0.05 and  ** p < 0.01.  
 
 
5.2.7 BLPs can induce alternatively activated macrophage phenotype.  
 
To investigate whether blocking bombesin/GRP signalling could affect cell 
viability or the phenotypes of activated MDMs, 1µM RC-3095 was added. 
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Addition of RC-3095 did not affect cell growth or the expression of various cell 
markers on LPS-stimulated MDMs (Fig. 5.7A and 5.7B).  
 
Reliable cell-surface markers of the classically activated macrophage (M1) 
phenotype are not well defined in humans, but M1 macrophages express CD16 
and CD86 upon activation. Alternatively activated macrophages (M2) express 
high levels of CD206 (mannose receptor) and CD163 (scavenger receptor) on 
the cell surface (285, 286). To determine whether H69 cell-derived BLPs could 
affect cell viability or macrophage phenotype polarization, MDM were matured, 
activated with LPS and co-cultured with H69 cells in the presence of RC-3095. 
Co-culture of MDMs with H69 cells or blocking bombesin/GRP signalling with 
RC-3095 did not affect the viability of MDMs (Fig. 5.7C). Flow cytometry studies 
identified no differences in the intracellular expression of CD68, or in the surface 
expression of CD80 or HLA-DR on LPS-activated MDMs among the different 
treatments (Fig. 5.7D). Interestingly, co-culture with H69 cells alone or in the 
presence of DMSO significantly reduced the surface expression of CD16 and 
CD86 on LPS-activated MDM compared to the MDMs cultured alone (Fig. 5.7E). 
However, the suppressive effect was completely reversed by addition of RC-
3095 (Fig. 5.7E).  The data suggest that SCLC cell-derived BLPs has no effect 
on MDM maturation, but can down-regulate CD16 and CD86 expression on 
MDMs in response to activation.  Furthermore, co-culture with H69 cells alone or 
in the presence of DMSO significantly up-regulated the surface expression of 
CD163 and CD206 on LPS-activated MDMs compared to the MDMs cultured 
alone (Fig. 5.7E). However, addition of RC-3095 completely prevented this 
increase (Fig. 5.7E). Together the data suggest that H69 SCLC cells may 
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Figure 5.7 BLPs induce alternatively activated macrophage phenotype. The experiments were 
performed as described in sections 2.6 and 2.12 Chapter 2.  (A) Viability of matured MDM 
cultured alone or with LPS in the presence of DMSO or RC-3095 assessed by MTT assay 
(Mean ± SEM, n=3 experiments). (B) Expression of CD68, CD14, CD16, CD80, CD86, HLA-DR, 
CD163 and CD206 on MDM (Geom. Mean ± SEM, n=3 experiments). (C) MDM viability 
assessed by MTT assay (Mean ± SEM, n=4 experiments). (D) Representative flow cytometry 
shows the intracellular expression of CD68 and cell surface expression of CD80 and HLA-DR, 
and bar graph shows the average fluorescence intensity (Geom.Mean ± SEM, n=4 
experiments). (E) Representative flow cytometry shows the expression of CD16, CD86, CD163 
and CD206, and bar graph shows the average fluorescence intensity (Geom.Mean ± SEM, n=4 
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5.2.8 BLPs suppress TNF-α and IL-6 production, and increases IL-10 
secretion from activated MDMs.  
 
To determine whether blocking bombesin/GRP signalling has an effect on TNF-
α secretion from MDMs upon activation, RC-3095 was used. LPS stimulation 
significantly increased TNF-α secretion, but addition of RC-3095 did not affect 
TNF-α production from LPS-activated MDMs (Fig. 5.8A).  
 
M1 macrophages are characterized by secretion of pro-inflammatory cytokines 
such as TNF-α, IL-6, IFN-γ and IL-1, resulting in an effective pathogen killing 
mechanisms.  Conversely, M2 macrophages release large amounts of anti-
inflammatory cytokines such as IL-10 or TGF-β, thus may suppress immune 
responses and contribute to tumour cell growth (278). BLPs produced by H69 
cells induced phenotypically M2-like macrophages (Fig. 5.7).  To investigate 
whether the M2-like macrophage induction is associated with alterations in 
cytokine secretion from MDM, the supernatants from cell culture of activated 
MDM co-culture with H69 cells in the presence of RC-3095 were collected. TNF-
α, IL-6, IFN-γ and IL-10 production was measured by ELISA.  
 
TNF-α and IL-6 secretion by MDMs was significantly increased with LPS 
stimulation, but was significantly reduced by co-culture with H69 cells (Fig. 5.8B 
and 5.8C). Addition of RC-3095 significantly reversed this suppressive effect 
(Fig. 5.8B and 5.8C).  There were no significant differences in IFN-γ production 
from activated MDMs cultured alone or in co-culture with H69 cells in the 
presence of RC-3095 or DMSO (Fig. 5.8D). IL-10 secretion from activated 
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MDMs was significantly increased by co-culture with H69 cells, but this increase 
was abrogated by addition of RC-3095 (Fig. 5.8E). The data demonstrate that 
H69 cell-derived BLPs can suppress TNF-α and IL-6 pro-inflammatory cytokine 
secretion and induce anti-inflammatory IL-10 production from MDMs in response 
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Figure 5.8: BLPs suppress TNF-α and IL-6 production, and increases IL-10 secretion from 
activated MDMs. (A) TNF-α concentration by MDM cultured alone, or activated with LPS or in 
the presence of DMSO or DMSO or RC-3095 assessed by ELISA (Mean ± SEM, n=3 
experiments). *** Indicates p < 0.0001. (B-E) TNF-α, IL-6, IFN-γ and IL-10 concentration by 
matured MDM, or LPS-stimulated MDM cultured alone or with H69 cells in the presence of 
DMSO or RC-3095 assessed by ELISA respectively (Mean ± SEM, n=3 experiments). * 
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5.3 Discussion  
 
The data presented in this chapter demonstrate that H69, H345 and H510 SCLC 
cells express GRP-R and that blocking bombesin/GRP signalling inhibits SCLC 
cell growth in concert with reductions in PI3K/Akt signalling. SCLC cell-derived 
BLPs can induce an M2-like alternatively activated macrophage phenotype from 
MDM in response to LPS activation. This polarization is associated with reduced 
secretion of TNF-α and IL-6, and increased production of IL-10 from LPS-
activated MDMs. This therefore represents another mechanism by which SCLC 
cells suppress the immune response.  
 
In this chapter, GRP-R expression is observed in H69, H345 and H510 SCLC 
cell lines at different levels. The data is consistent with early studies showing 
that GRP-R mRNA can be detected by RT-PCR in majority of SCLC cell lines 
including H69 and H345 cells (287, 288). The expression of GRP-R is much 
more commonly found in various human malignancies than in normal tissues 
(56). In addition, GRP-R expression in lung tissues has been reported to be 
significantly elevated with tobacco exposure (289) and cigarette smoke is the 
most significant risk factor for lung cancers. Therefore, GRP-R expression is 
often overexpressed in lung cancers (264) and is more frequent in lung cancer 
patients than cancer-free control subjects (290). The data presented here show 
that GRP-R is expressed on primary tumour biopsies from SCLC patients. The 
data are consistent with other studies demonstrating that GRP-R mRNA is 
detectable in SCLC tumour cells (291) and GRP-R is expressed on tumour 
biopsies from a large population of patients with SCLC (292).  Future 
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experiments to study whether the expression of GRP-R on tumour biopsies is 
associated with patient survival in SCLC may now be indicated.  
 
Blocking bombesin/GRP signalling with the GRP-R antagonist RC3095 inhibits 
H69, H345 and H510 SCLC cell growth in vitro. These data are consistent with 
early studies demonstrating that BLPs are autocrine growth factors in SCLC 
(103). Similar effects of RC-3095 have been shown to inhibit SCLC cell growth 
in vivo. In animal studies, subcutaneous treatment of nude mice xenografted 
with human H69 SCLC cells with bombesin significantly increased tumour 
weight (293). However, blocking bombesin/GRP signaling with RC-3095 
significantly reduced the tumour volume by 50-70% (294). Similarly, RC-3095 
reduced tumour growth in nude mice xenografted with human H128 SCLC cells 
(64). In addition, blocking bombesin/GRP activity with analogues or with other 
receptor antagonists can also inhibit SCLC tumour cell growth in vivo and in 
vitro (295-297).  The suppressive effect of RC-3095 on SCLC cell proliferation is 
dose-dependent.  Addition of RC-3095 at concentrations of 5 µM and 10 µM 
suppress SCLC tumour cell growth, whilst 1 µM has no effect. The data are 
consistent with a previous observation demonstrating that bombesin does not 
stimulate the proliferation of SCLC cell lines at concentrations between 0.1 nM 
and 1 µM (298). The reduced cell viability is associated with reduced 
phosphorylation of Akt in SCLC cells, supporting the hypothesis that the 
PI3K/Akt signaling pathway may mediate proliferation in SCLC cells.  
 
Neuropeptides play an important role in the regulation of function and survival of 
immune cells (299). There are no previous data on the interactions between 
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SCLC-derived BLPs and immune cells. The data in this chapter demonstrate 
that blocking bombesin/GRP signalling has no effect on the suppressive effect 
of H69 cells on CD4+ T cell proliferation, but reverses their MLR suppressive 
effects. Therefore, such BLPs secreted by H69 cells may not be responsible for 
the direct observed suppression of CD4+ T cell proliferation, but instead act on 
other immune cells to inhibit their capacity to induce T cell proliferation (271, 
300). On the other hand, lack of effect of RC-3095 at the concentration of 1 µM 
on the suppression of T cell proliferation may be due to insufficient dose, future 
experiments with a series of concentrations of RC-3095 need to be performed to 
address this issue.  
 
GRP-R is expressed by monocytes and monocyte-derived macrophages 
(MDMs), and its expression is significantly up-regulated by co-culture with H69 
cells. The data suggest that H69 cell-derived bombesin/GRP could affect 
monocytes or MDMs through its interaction with GRP-R. Other studies have 
demonstrated that GRP-R is expressed by immune cells (301) and GRP may 
modulate monocyte and macrophage activities (272-274).  Recent studies have 
shown that GRP can induce inflammation (302, 303). Blocking GRP activity with 
RC-3095 has anti-inflammatory effects in arthritis and sepsis models, down-
regulating the production of pro-inflammatory cytokines TNF-α, IL- 1β and IL-6 
(304). The data in this chapter demonstrate that the secretion of TNF-α from 
LPS-activated monocytes is suppressed by co-culture with H69 cells or H69 
culture supernatant and that this suppression is mediated by bombesin/GRP 
signaling.  
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H69 cell-derived BLPs have no effect on MDM survival but can modulate the 
phenotype and function of MDM upon activation. The expression of CD16 and 
CD86 is significantly down-regulated on LPS-activated MDMs. CD16, the 
receptor for the Fc portion of IgG, is important in antibody-mediated cell 
cytotoxicity and CD86 is an important co-stimulatory molecule for T-cell 
activation and proliferation (285). M1 macrophages are tumoricidal, function as 
antigen-presenting cells and express high levels of CD16 and CD86 on the cell 
surface (285, 305). Therefore, down-regulation of these surface molecules by 
SCLC cell-derived BLPs may inhibit the anti-tumour function of macrophages 
and prevent activation of T cells within the tumour microenvironment. It has 
been shown that in some solid tumours, although abundant macrophages are 
found, there is little evidence of immune rejection, and the local tumour 
microenvironment is immunosuppressive with few CD8+ cytotoxic and CD4+ 
effector T cell infiltration (306). This may be associated with reduced expression 
of CD16 and CD86 on the surface of antigen presenting cells, which could 
impair their capacity to activate effective immune responses.    
 
In addition, H69 cell-derived BLPs significantly increase the expression of 
CD163 and CD206 on MDM upon activation. CD163 (scavenger receptor) and 
CD206 (mannose receptor) are both highly expressed on M2 macrophages that 
are characterized by high phagocytic capacity and anti-inflammatory cytokine 
production (286, 307). Macrophages co-expressing CD163 and CD206 have 
high capacity for apoptotic cell uptake and produce high levels of IL-10 and 
CCL18 (308, 309). The data in this chapter suggest that upon activation, rather 
than being M1 tumoricidal macrophages, MDMs can be induced to M2-like 
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immunosuppressive phenotype macrophages by SCLC cell-derived BLPs. This 
may support the recent studies on substance P (SP), another neuropeptide that 
is associated with SCLC cell growth (310), demonstrating that SP is able to shift 
macrophages to an M2 activation state and induce CD163 expression (311, 
312).  
 
The modulation of macrophage cell surface phenotype mediated by H69 cell-
derived BLPs is validated by the findings of consistent alterations in cytokine 
production. In the presence of GM-CSF and LPS stimulation, macrophages are 
induced to adopt an M1 phenotype and produce high levels of pro-inflammatory 
cytokines including TNF-α, IL-6, IL-12 and IL-1β (285, 286). M2 macrophages 
are characterized by low production of these pro-inflammatory cytokines and 
high production of the anti-inflammatory cytokine IL-10 (285, 286). The data in 
this chapter demonstrate that the secretion of TNF-α and IL-6 is significantly 
reduced and IL-10 production is significantly increased from MDMs activated 
with LPS through GRP-R signalling. The data therefore indicate that SCLC cell-
derived BLPs may induce a switch from M1-like to M2-like macrophage 
phenotype in terms of both cell surface markers and cytokine production. 
Polarization of macrophages to an M2-like phenotype by proximity to SCLC cells 
may therefore represent another mechanism by which SCLC tumours can 
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Chapter 6: Identification of an Independent Prognostic 
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Immune cells in the tumour microenvironment can eradicate malignant cells and 
control tumour growth. Tumour-infiltrating lymphocytes (TILs), macrophages and 
dendritic cells (DC) that are commonly found in solid tumours have been 
associated with improved patient survival and reduced relapse in various cancers 
(313-317). However, some studies have demonstrated that, although multiple 
immune cell types commonly infiltrate solid tumours, they may fail to demonstrate 
effective, consistent and durable anti-tumour responses (318). One of the most 
important reasons may be that FoxP3+ Treg cells within the tumour 
microenvironment play a significant role in suppressing anti-tumour immune 
responses (176).  
 
The published data on the impact of Treg infiltration in the tumour 
microenvironment on patient survival is, however, controversial.  The presence of 
higher proportions of CD4+FoxP3+ Treg cells among TILs has been associated 
with poor survival in melanoma, ovarian, breast and gastric cancers (224, 319, 
320). In contrast, other reports demonstrate that large numbers of Treg cell 
infiltration is associated with improved survival in Hodgkin lymphoma, head/neck, 
urinary bladder and colon cancers (321-324). Furthermore, FoxP3+ cell infiltration 
has been reported to have no prognostic impact in patients with malignant 
melanoma or prostate cancer (325, 326). In SCLC, the local immune cell infiltrate 
and specifically the impact of infiltrating FoxP3+ cells has not been extensively 
studied. In this chapter the presence of FoxP3+ Treg cells within the primary 
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tumour microenvironment and the impact of Treg cell infiltration on patient survival 
are quantified for an SCLC cohort.    
 
SCLC has a very poor prognosis despite treatment (10). Currently, only a small 
number of indicators, most of which are clinical markers (performance status, 
disease stage, age and sex) can be used to stratify patients with SCLC into 
prognostic groups (177). Early studies have demonstrated that some immune 
parameters may predict SCLC patient prognosis and disease stage. These 
include the degree of delayed hypersensitivity reaction and defects in peripheral 
blood lymphocyte numbers, proliferative response and IL-2 secretion (327-329). 
However, these studies have focused on the assessment of systemic immune 
responses that may not reflect the relevant changes in the local tumour 
environment. Immunohistochemical analyses of the local tumour inflammatory 
microenvironment in SCLC may reveal novel prognostic markers that should be 
simple and reproducible in a diagnostic laboratory. I undertook to profile immune 






















6.2.1 SCLC tumour sections are infiltrated by various mononuclear immune 
cells.   
 
In a pilot experiment to determine whether immune effector cells infiltrate SCLC 
and to identify the types, population and location of tumour-infiltrating immune 
cells, paraffin-embedded sections from 12 surgically resected SCLC tumours were 
immunohistochemically stained and viewed with light microscopy. Firstly, the 
leukocyte surface marker CD45 was used as a pan-inflammatory cell marker to 
stain mononuclear immune cells. CD45 did not stain SCLC tumour cells but 
CD45+ cells were readily seen in tumour microenvironment in 12/12 patients (Fig. 
6.1A). Tumour infiltrating CD45+ cells were observed both within the tumour 
stroma (peritumoral) and in the tumour mass (intratumoral)  (Fig. 6.1A).  
 
To further characterize the cellular composition of CD45+ infiltrates, CD3 (T cell 
marker), CD20 (B cell marker), CD14 (monocyte marker) and CD68 (macrophage 
marker) were used. CD3+ cells were found in 12/12 SCLC tumour biopsy samples 
and were predominantly present in the tumour stroma, there were more CD3+ 
cells within the stroma than the tumour mass (Fig. 6.1B). CD4+ and CD8+ T cells 
were identified in 12/12 SCLC sections. CD4+ T cells showed a similar distribution 
to CD3+ T cells in 12/12 patients. In contrast, 10/12 patients showed greater 
numbers of CD8+ T cells infiltrating the tumour mass compared to peritumoral 
stroma (Fig. 6.1B).  CD20+ B cells were observed in low numbers compared to 
CD3+ T cells, and were only present in the peritumoral stroma in 9/12 SCLC 
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tumour biopsies (Fig. 6.1B). 12/12 patients showed that CD14+ monocytes and 
CD68+ macrophages were both present within the tumour microenvironment. 
Fewer of these cells infiltrated the tumour mass compared to the peritumoral 
stroma (Fig. 6.1B).  
 
 




Figure 6.1: SCLC tumour sections are infiltrated by various mononuclear immune cells. 
Representative images of immunohistochemistry (IHC) showing (A) tumour infiltrating CD45 
positive cells (intratumoral and peritumoral) and negative control. (B) CD3, CD4, CD8, CD20, 




6.2.2 SCLC tumour sections are infiltrated by FoxP3+ Treg cells.  
 
Tumour-infiltrating lymphocytes (TILs) include populations of both effector and 
Treg cells. A preponderance of Treg cells may lead to a failure of tumour 
immunosurveillance and contribute to the progression of cancer (330). FoxP3 
staining was undertaken to determine the presence, population and distribution of 
Tregs in SCLC tumour microenvironment. CD3+ T cells including CD3+FoxP3+ 
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Treg cells and CD3+FoxP3- effector cells were present in the tumour tissues, some 
CD3+ T cells, but none of the tumour cells, were positive for nuclear FoxP3 (Fig. 
6.2A).  A number of FoxP3+ cells were observed in the tumour stroma 
(peritumoral) but none in the tumour mass (intratumoral) (Fig. 6.2B). The data 
indicate that the presence of Treg cells in the tumour stroma may contribute 




Figure 6.2 SCLC tumour sections are infiltrated by Treg cells. (A) Representative images of 
immunofluorescence (IF) staining showing SCLC sections simultaneously assessed for CD3+ T 
cells, FoxP3 transcription factor, all nucleated cells (DAPI) and merged image. High power images 
of merged stains showing CD3+FoxP3+ and CD3+FoxP3- cells isolated as indicated.  (B) IHC 
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6.2.3 FoxP3+ cell infiltration does not predict patient survival in SCLC.  
 
Considerable variability in the amount of FoxP3+ cell infiltration among SCLC 
patients was observed, suggesting a biologically heterogeneous response (Fig. 
6.3A). To determine whether FoxP3+ cell infiltration may represent a prognostic 
marker of survival, IHC staining for FoxP3 on the tumour biopsies from 64 SCLC 
patients was performed. The details of study cases were collected and 
summarized (Table 6). The average number of FoxP3+ cells per high-power field 
(hpf) was determined for each SCLC tumour sample. The positive cells were 
counted under X 400 magnification hpf/tumour sample, and the area of the field at 
this magnification was 0.18mm2.  10 random high-power fields were counted per 
stain per biopsy and the score per field was averaged. Fields were not selected if 
they did not contain tumour cells. Analysis of interobserver variability showed no 
statistical differences between the mean counts achieved by the observers (Wei 
Wang and Prof T Sethi, King’s College London, Dr W Wallace, University of 
Edinburgh).  
 
The number of FoxP3+ cells counted per field ranged from 1 to 40 with an average 
number of 8 per high-power field. Kaplan-Meier survival plots were devised by 
dividing the study group around the average value (8) (FoxP3 > 8, n=34; FoxP3 < 
8, n=30).  The patients with FoxP3+ cell count > 8 did not show significant 
difference in survival compared with those with FoxP3+ cell infiltration < 8 on 
tumour biopsies in SCLC (> 8 average of overall survival: 293.5 days; < 8 average 
overall survival: 230.5 days) (Fig. 6.3B). The data suggest that differences in 
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Foxp3+ Treg cell infiltration between patients may not represent a significant 
prognostic marker in SCLC. 
 
 
Table 6. Summary of details of SCLC study cases. Data are presented as number unless indicated 
otherwise. ECOG= Eastern Cooperative Oncology Group. 
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Figure 6.3: FoxP3+ cell infiltration does not predict patient survival in SCLC. (A) Representative 
images of immunohistochemistry (IHC) staining showing low and high FoxP3+ cell infiltration on 
tumour biopsies from SCLC patients. (B) Kaplan-Meier plots showing the survival of SCLC patients 
with FoxP3+ cell count greater than or less than the average value of 8 cells per X400 
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6.2.4 CD45+ cell infiltration is a predictor of survival in SCLC.  
 
CD45+ leukocytes were observed to be present in tumour site and the cell number 
varied between patients in SCLC (Fig. 6.4A). To determine whether CD45+ cell 
infiltration represent a prognostic marker to predict survival in SCLC, IHC staining 
for CD45 on 64 SCLC tumour sections. Both intratumoral and peritumoral CD45+ 
cells were counted as tumour infiltrates and CD45 positive cell counting per field 
per biopsy were performed as described above.  
 
The number of CD45+ cells counted per field ranged from 3 to 127 with an 
average value of 37.6 per high-power field. Univariate analysis of survival times 
was performed using Kaplan-Meier plots that were devised by dividing the study 
group around the average value (38) (CD45 > 38, n=30; CD45 < 38, n=34).  The 
patients with CD45+ cell number above the average survived significantly longer 
compared with those with CD45+ cell infiltration less than 38 (P < 0.0001) (Fig. 
6.4B).  The average survival of patients in “high” CD45 count group was 534 days 
compared with the average survival time of 137.5 days in the group with fewer 
CD45+ cells. Only 3% of the patients with a CD45 < 38 survived 1000 days 
compared with 27% of those with a CD45 > 38 (P < 0.01). No relationship 
between CD45+ cell number and age (P = 0.63), sex (P = 0.36), stage (P = 0.17), 
or treatment by chemotherapy (P = 0.12) or radiotherapy (P = 0.28) was identified 
(χ2 test). The data suggest that CD45+ cell infiltration into tumour biopsy samples 
may be considered as a prognostic marker to predict survival in SCLC.  
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Figure 6.4:  CD45+ cell infiltration is a predictor of survival in SCLC. (A) Representative 
immunohistochemistry (IHC) showing low and high CD45+ cell infiltration in tumour biopsies from 
SCLC patients. (B) Kaplan-Meier plots showing the survival of SCLC patients with CD45+ cell 
count greater than or less than the median value of 38 cells per X400 magnification field.  
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6.2.5 The ratio of FoxP3+/CD45+ in SCLC tumour biopsy infiltrates negatively 
correlates with patient survival.  
 
To determine the relationship between Treg cells in total leukocyte infiltrates of 
SCLC tumour biopsies and patient survival, the ratio of FoxP3+ : CD45+ cells from 
the same biopsy was examined as a measure of proportion of Treg cells in the 
infiltrating leukocyte population. The ratios of FoxP3+ : CD45+ cells from the 64 
cases had a range from 3% to 80% with a median value of 28% per field per 
biopsy. The effect on patient survival time was determined using Kaplan-Meier 
analysis that was devised by dividing the study group around the median value 
(28%) (FoxP3/CD45 > 28%, n=31; FoxP3/CD45 < 28%, n=33).  The patients with 
FoxP3+ : CD45+ ratios above 28% had significantly worse overall survival 
compared with those with the ratios lower than 28% (P = 0.04) (Fig. 6.5). The 
average survival in “high” ratio group was 177.5 days compared with an average 
of 336.5 days in the group with the ratio less than 28%.  The data indicate that the 
increased proportion of Treg cells in the leukocyte infiltrate within the tumour 
microenvironment is associated with poor survival in SCLC.  
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Figure 6.5: The ratio of FoxP3+/CD45+ in SCLC tumour biopsy infiltrates negatively correlates with 
patient survival. Kaplan-Meier plots showing the survival of SCLC patients with the ratio of 
FoxP3+/CD45+ on tumour biopsies greater than or less than the median value of 28% per X400 
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6.3 Discussion  
 
The data in this chapter demonstrate that a number of immune cell types including 
CD3+FoxP3+ Tregs are present in the primary tumour microenvironment in SCLC. 
FoxP3+ cell infiltration alone does not predict patient survival. However, patients 
with higher numbers of CD45+ cells in tumour infiltrates have a highly significant 
survival advantage irrespective of disease stage, incidence of infection, sex, age 
and treatment.	    Therefore, CD45+ cell infiltration in the tumour biopsies may 
represent an independent and significant prognostic marker to predict survival in 
SCLC. Furthermore, a relatively high proportion of FoxP3+ Tregs in the total 
CD45+ leukocyte infiltration negatively correlates with patient survival.   
 
Previous studies in SCLC have demonstrated that high numbers of tumour 
infiltrating lymphocytes and macrophages are associated with small tumour sizes 
and improved patient survival (331). The same observations have been found in 
other cancers (313-317). These studies suggest the local immune cell infiltrate in 
tumour microenvironment may play a crucial role in control of cancer growth. The 
data presented here clearly demonstrate the presence of a CD45+ mononuclear 
immune cell infiltrate in the human SCLC microenvironment. This leukocyte 
infiltrate consists of CD3+ T cells (CD4+ and CD8+), CD20+ B cells, CD68+ 
macrophages and CD14+ monocytes. The presence of these cells may represent 
a specialised and complex host immune response to the tumour cells in SCLC. 
 
Histologic assessments of local immune responses to tumour as a prognostic 
marker have been proposed in many tumour types. However, there are no such 
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markers identified in SCLC. The data presented here indicate an early, steep fall 
in survival in the “low” CD45+ cell number group. Patients with  “high” numbers of 
CD45+ infiltrate survive significantly longer, which may be associated with better 
host anti-tumour responses and thus may impair tumour growth and prolong 
survival. This is independent of other well-described prognostic markers including 
patient age, sex, stage or treatment. Therefore, the number of CD45+ cells in the 
tumour microenvironment has a predictive effect on overall survival and can be 
regarded as an independent prognostic marker.  Some previous studies in other 
tumour types have specifically identified infiltrating inflammatory cells as 
“intratumoral” or “peritumoral” in location (332, 333). In this study, CD45+ cells in 
both locations are all considered as tumour infiltrating cells and could reasonably 
be regarded as “tumour associated”. This is because the recruitment and retention 
of CD45+ cells to the fragments of tissue at that site is likely related to the 
presence of the tumour. Importantly, the assessment of CD45+ cell infiltrate as a 
prognostic marker by immunohistochemical stain in SCLC tumour biopsy samples 
can be routinely performed in a diagnostic laboratory. This method, being based 
on counting positive cells in high power field from fragments of tumour tissue, is 
relatively simple and reproducible, and may provide prognostic information without 
the requirement for additional complex investigations.  
 
FoxP3 is considered as a marker of Treg cells (334). However, it has been shown 
that FoxP3 is expressed both at the transcript and protein level by tumour cells of 
various types (335). FoxP3+ cells in SCLC tumour biopsies are confirmed as Treg 
cells by immunofluorescent double staining for CD3 and FoxP3, and SCLC tumour 
cells do not express FoxP3.  FoxP3+ cells are predominantly present in the tumour 
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stroma and very rarely infiltrate in tumour mass, similar to observations from other 
tumour types (325, 336). The amount of FoxP3+ cells in tumour sections does not 
show association with any parameters of SCLC cases, and FoxP3+ cell infiltration 
alone does not predict patient survival. Previous studies demonstrate 
contradictory results, showing that Treg cell infiltration in different cancers has 
been associated with all possible outcomes - poor survival  (224, 319, 320), 
improved survival (321-324) and no correlation (325, 326). It may be that tumour 
types behave differently in this context (337), depending on other components of 
the complex anti-tumour immune responses and/or the interactions between 
tumour cells and Treg cells (224). These discordant observations suggest 
significant heterogeneity between different tumour types in terms of the impact of 
peritumoral Treg cells on patient outcome.   
 
The distribution of Treg cells is different from CD45+ immune cell infiltrates. Treg 
cells are restricted to the peritumoral stroma in SCLC while CD45+ cells are in 
both peritumoral and intratumoral. These Tregs cells may reduce the recruitment 
of anti-tumour CD45+ cells during tumour progression in SCLC. The suppressive 
effect on CD45+ cell recruitment may be achieved by preventing immune effector 
cells from infiltrating to tumour sites and/or by suppressing proliferation of immune 
cells (211). Indeed, the patients with increased proportion of Treg cells in CD45+ 
cell tumour infiltrates have a significantly worse survival rate. This may be, at least 
in part, because, the patients with higher FoxP3+ ratios have a worse local anti-
tumour immune response.  
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7.1 Conclusion  
 
The general importance of immune surveillance in preventing cancer is 
indicated by the increased incidence of malignancy associated with 
immunosuppressive therapy (175, 176). Conversely, local and systemic 
immunosuppressive effects of tumour cells (106,107), including SCLC cells 
(160,161), mediate tumour tolerance. In SCLC such defects correlate with worse 
morbidity and mortality (160, 161). The work presented in this thesis support a 
range of immunomodulatory interactions between SCLC tumour cells and 
immune cells. Different SCLC tumour cell lines inhibit cell-mediated immune 
responses to differing extents through suppressing proliferation of a mixed 
leukocyte reaction and CD4+ T cells (Chapter 3). Two important mechanisms by 
which SCLC tumour cells may suppress local and systemic immune responses 
have been identified. Firstly, SCLC cells can secrete IL-15 to induce CD4+ T 
cells to adopt a functional Treg phenotype (Chapter 4). Secondly, SCLC cells 
can secrete BLPs to induce macrophage populations polarized towards an 
immunosuppressive, alternatively activated M2-like phenotype (Chapter 5). 
These novel findings may highlight potential new therapeutic targets to improve 
immune response and patient survival in SCLC.   
 
SCLC has very poor prognosis and only a small number of indicators can be 
used to stratify SCLC patients into prognostic groups (177). These include 
clinical markers such as performance status (PS), disease stage (LD or ED), 
age, and sex (177). Histologic assessments of local immune responses to 
tumour as a marker of prognosis have been studied in this work.  CD45+ 
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immune cells and FoxP3+ Treg cells are found in tumour biopsies in SCLC 
patients (Chapter 6). CD45+ cell tumour infiltrates have a prognostic effect on 
patient survival that is independent of age, sex, stage, or treatment (Chapter 6). 
Therefore, it may represent an independent and significant prognostic marker in 
SCLC. The proportion of FoxP3+ Treg cell: total CD45+ leukocyte within tumour 
microenvironment (but not absolute FoxP3+ cell count alone) negatively 
correlates with patient survival in SCLC. These novel findings have defined 
simple and reproducible prognostic markers that may assist medical decision 
making and improve future research design.   
 
 
7.2 Identification of factor(s) that can induce the Treg population to 
suppress CD4+ T cell proliferation.  
 
The data presented in Chapters 3 and 4 demonstrate that three different SCLC 
cell lines have differential immunosuppressive effects on MLR and CD4+ T cell 
proliferation and induction of functional FoxP3+ Treg cells.   These effects are in 
a consistent order H510<H345<H69 and may be associated with the levels of 
soluble factors that are constitutively produced by SCLC cells. These molecules 
are not IL-10 or TGF-β as neutralization of both fail to reverse the suppressive 
effect on T cell proliferation. BLPs produced by H69 cells are ruled out in 
Chapter 7, showing that blocking BLP signalling has no effect on suppression. 
IL-15 has been identified as one, but not the only, soluble factor produced by 
H69 cells that can mediate immune suppression. This is because blocking of IL-
15 activity only partially reverses the suppression of CD4+ T cell proliferation 
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and induction of Treg cells. Furthermore, the combination of IL-15 and H510CM 
induces similar Treg cell population to IL-15 alone and less than H69CM. These 
data indicate that H69 cells secrete other soluble factors that are involved in 
Treg cell induction and that are not secreted by H510 cells. In addition to IL-15, 
a number of cytokine genes (IL-1α, IL-11, IL-16, BMP-7 and CSF-2) are up-
regulated in H69 cells relative to H510 cells. The effects of these cytokines on 
Treg cell induction should be the focus of future experiments.  
 
In addition to inhibitory cytokines (IL-10 and TGF-β), other immunosuppressive 
factors derived from tumour cells such as indoleamine 2,3-dioxygenase (IDO), 
vascular endothelial growth factor (VEGF), adenosine and galectins, have been 
described in other cancers (332). High levels of IDO1 produced by tumour cells 
can induce FoxP3+ Treg cell population and directly suppress T cell activity 
(339). The presence of VEGF may induce immunosuppression by affecting the 
maturation of DCs and macrophages (340). Adenosine is secreted by tumour 
cells and immune cells during tumor pathogenesis. It can exert 
immunomodulatory effects via its different receptors expressed on various 
immune cells including Treg cells (341). Moreover, galectins produced by 
tumour cells can suppress anti-tumour responses by affecting phenotype and 
function of various immune cells (342). Assessments of the presence and 
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7.3 The effects of IL-15 in anti-cancer immune responses.  
 
The role of IL-15 in human cancers is complex.  IL-15 can either function as an 
immune-stimulatory cytokine to boost host immune responses or function as a 
growth factor to promote tumour cell proliferation and migration (343-345). IL-15 
is produced by a variety of cells and has various functions in regulation of 
immune responses. These functions include stimulating the proliferation, 
differentiation and activation of NK cells, NK-T cells, CD4+ and CD8+ T cytotoxic 
cells, B cells, monocytes and APCs (254, 346). Therefore, IL-15 has been 
promoted as a potential anti-tumour therapy to boost immune responses against 
cancers, and some clinical trials using IL-15 are being performed (343-345). In 
fact, IL-15 used alone, or in combination with other treatment modalities, has 
been shown to improve immune responses in solid tumours. However, IL-15 has 
been found to be associated with inflammation that may be linked to cancer 
pathogenesis (346). Furthermore, IL-15 can also act as a growth factor to inhibit 
apoptosis of tumour cells and promote their proliferation and migration, thereby 
leading to tumour progression and metastasis (343). Therefore, the use of IL-15 
in cancer immunotherapy requires some caution, at least in principle, and its 
effects upon the specifically targeted tumour cells should be examined carefully 
in different cancers.  
 
Despite a growing interest in the use of IL-15 as an immunotherapeutic agent, 
the broad spectrum of immunomodulatory functions exerted by IL-15 has not 
been fully elucidated. IL-15 and IL-2 have a number of similar functions to 
potentiate the immune system (344). However, IL-15 has pleiotropic effects on 
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Treg cells in contrast to IL-2, which plays a critical role in the differentiation and 
maintenance of FoxP3+ Treg cells (338).  The data presented in Chapter 4 
demonstrate that SCLC cell derived-IL-15 may play a role in SCLC 
pathogenesis to induce Treg cells that suppress CD4+ T cell proliferation. This is 
consistent with other studies showing that IL-15 can induce a population of 
FoxP3+ Treg cells (235, 257-260). On the other hand, IL-15 can render effector 
T cells resistant to suppressive effects of Treg cells and reverse the tolerance of 
effector T cells to tumour-associated antigens (TAAs) (343). Induction of Treg 
cells that induce tolerance to TAAs and suppress the anti-tumour immune 
responses represents a major obstacle to the development of effective tumour 
immunotherapies (176). Therefore, reduction of Treg cell population in tumour 
sites may improve cancer immunotherapy. In SCLC, IL-15 may represent a 
potential new therapeutic target to improve immune response and patient 
survival.  
 
7.4 The mechanisms of SCLC cell-induced Treg cell suppression. 
 
It is well established that iTregs can exert their suppressive activity on effector T 
cells by secreting large amounts of the potent immunosuppressive cytokines IL-
10 and TGF-β (214). The data in Chapters 3 and 4 demonstrate that SCLC cells 
induce an increased population of Treg cells by adaptive induction from naïve 
CD4+ T cells. These iTreg cells can suppress the proliferation of effector CD4+ T 
cells (Chapter 4). However, the suppressive effect of SCLC cell-induced Treg 
cells is not mediated through the production of immunosuppressive cytokines IL-
10 or TGF-β (Chapters 3 and 4). This suggests that SCLC cells may induce a 
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distinct subtype of iTregs relative to those have previously been described. 
Future experiments may need to investigate the mechanisms of SCLC cell-
induced Treg cell suppression and the phenotype of the resultant iTregs.  
 
A number of possible alternative mechanisms may underlie the 
immunomodulatory effects of such iTreg cells (239). These include pathways 
mediated by IL-35 and granzymes. IL-35, a new member of IL-12 cytokine 
family, has been discovered as a new inhibitory cytokine that can that can 
directly inhibit effector T cell proliferation in mouse (347). Human Treg cells do 
not constitutively express IL-35 (348). Nevertheless treatment of naïve human T 
cells with IL-35 induces Treg cells with suppressive effects by stimulating IL-35 
production and this process does not require IL-10, TGF-β or FoxP3 (349). In 
vitro studies indicate these Treg cells need to be activated for a prolonged 
period to exert suppressive effects, and that these mechanisms are independent 
of direct cell contact (350). Future experiments can be performed to determine 
whether blocking of IL-35 has effects on Treg cell induction and the suppression 
of CD4+ T cell proliferation.  
 
Granzymes are serine proteases, secreted mainly by NK cells and CTLs.  They 
are largely responsible for the induction of apoptosis in target cells (351). The 
perforin/granzyme pathway is one of the key mechanisms by which Treg cells 
mediate immune suppression (239). Activated Treg cells are capable of killing 
autologous target cells in a cell contact-mediated and perforin-dependent 
manner. Specific granzymes are utilized by nTregs (granzyme A) and iTregs 
(granzyme B) (342, 353).  Similarly, in mice, Treg cells derived from the tumour 
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environment highly express granzyme B, and mediate immune suppression in a 
granzyme B and perforin-dependent fashion in vivo (354). Interestingly, in mice, 
it has also been shown that contact-mediated suppression by Treg cells involves 
a granzyme B-dependent, perforin-independent mechanism (355). Future 
experiments can be performed to determine the expression of granzyme A/B in 
SCLC cell-induced Tregs, whether these cells are cytotoxic to autologous 




7.5 The phenotype and function of tumour-associated macrophages 
(TAMs) in SCLC.   
 
Inflammatory cells and mediators are important constituents of the local tumour 
microenvironment (356). Tumour-associated macrophages (TAMs) are a major 
component of the host immune cell infiltrate of tumours, and the recruitment of 
circulating monocytes is essential for TAM infiltration (144). Tumoricidal M1-like 
and pro-tumoral M2-like macrophages are the main two types of TAMs with 
diverse phenotypes and functions, they both significantly correlate with tumour 
initiation and progression (143, 144). Previous studies have suggested that 
TAMs could be either M1- or M2-like macrophages (357). In vitro studies in this 
thesis demonstrate that upon activation, monocyte-derived macrophages (MDM) 
have a mixed phenotype expressing both M1 and M2 markers (Chapter 5). 
However, they are polarized to an M2-like phenotype by SCLC cell-derived 
BLPs. Specifically, the polarization is associated with reduced expression of M1 
	   191	  
markers (CD16/CD86) and increased expression of M2 markers 
(CD163/CD206). In addition, the polarization is accompanied by a reduction in 
pro-inflammatory cytokine secretion (TNF-α/IL-6) and an increase in 
immunosuppressive cytokine production (IL-10) (Fig. 7). Therefore, SCLC cells 
have the potential to induce immunosuppressive populations of TAMs within the 
tumour microenvironment.  
 
However, the phenotype and function of TAMs in vitro may not directly reflect 
their plasticity in vivo within the complex tumour microenvironment. Accurate 
identification and characterization of these various populations of TAMs within 
the tumour microenvironment may highlight therapeutic targets and predict 
prognosis. It has become clear that TAMs are composed of multiple distinct 
populations with overlapping features. These depend on a variety of external 
factors including characters of activation in the complex tumour 
microenvironment, stage and type of cancers (143, 358). Studies of NSCLC 
tumour biopsies have revealed that the TAMs are composed of both M1 and M2 
macrophages (359, 360). The presence of the M1 form in TAMs is positively 
associated with patient survival, whilst M2 macrophages with 
immunosuppressive function are predominant population of TAMs and the M2 
density also correlate patient survival (359, 360). 
 
Previous studies have tried to relate TAM infiltration to prognosis in human lung 
cancer, with various results including positive, negative and no correlation (361). 
In SCLC, these have not been extensively studies.  The data presented here 
demonstrate the presence of CD68+ macrophages in tumour biopsy samples 
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from SCLC patients. Future experiments are required to investigate the 
phenotype of TAMs in SCLC tumours in vivo using multiple phenotypic markers, 
and to determine their effects on patient survival in SCLC. Future studies may 
then usefully investigate their effects on proliferation of CD4+ T cells and 
induction of Treg cells.   
 
 
7.6 Causes and implications of differential immune cell infiltration in SCLC 
in vivo.   
 
7.6.1 Differential immunosuppression by SCLC in different patients may 
account for CD45+ cell infiltrate variability.    
 
The data presented in chapters 4 and 5 demonstrate that IL-15 and BLPs 
produced by SCLC cells in vitro can induce functional Treg cells and 
immunosuppressive M2 macrophages respectively. Other factors produced by 
SCLC cells may also contribute to the suppressive effects on anti-tumour 
immune responses. In vivo production of these factors may suppress the local 
host immune responses by acting upon different types of CD45+ cells. 
Differences in the production of these factors within the tumour 
microenvironment would thereby affect the recruitment and retention of immune 
cells. This may explain the observed differences in CD45+ leukocyte infiltrates 
and patient survival. Indeed, the data in chapter 5 demonstrate that the 
proportion of Foxp3+ Treg cells to CD45+ leukocytes in tumour infiltrates 
significantly correlates with patient survival. Future experiments usefully 
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investigate IL-15 and BLP expression in SCLC tumour samples and correlate 
the expression with immune cell infiltrates and patient survival.  
 
 
7.6.2 CD45+ cell number within tumour microenvironment is considered as 
an independent prognostic marker.   
 
Histologic assessments of SCLC tumour biopsies indicate that the presence of 
CD45+ cells within the tumour microenvironment may represent a specific anti-
tumour immune response (Chapter 6). CD45+ cell infiltration within the tumour 
microenvironment may eradicate malignant cells and control tumour growth, and 
the patients should benefit in survival. If so, then patient survival may correlate 
with CD45+ cell infiltration into tumour tissues. I have studied this in a cohort of 
64 typical SCLC patients for whom clinical details are available. The ex vivo 
data support this hypothesis. Patients with higher numbers of CD45+ cells within 
the tumour microenvironment have a highly significant survival advantage 
irrespective of disease stage, incidence of infection, sex, age and treatment. 
The study is relatively small, and retrospective. It may be built upon by future 
studies by assessing more SCLC tumour samples prospectively by 
immunohistochemical methods to assess CD45+ cell numbers. In addition, the 
biopsies should be stained with Ki67 (proliferation marker), CD34 (angiogenesis 
marker) and TUNEL (apoptosis marker), to determine the effects of CD45+ cell 
infiltration on tumour cell growth. 
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7.6.3 Identification of other immune cell infiltrates as prognostic markers.    
 
Different types of immune cells are recruited to the tumour sites, their 
distribution, tissue localization and function are significantly associated with 
tumour progression and patient survival (362). Various mononuclear immune 
cells have been found in SCLC tumour biopsy samples (Chapter 6). 
Assessment of individual immune cell types within tumour microenvironments 
may be more accurate than assessment of total CD45+ inflammatory cells in 
prediction of patient prognosis. CD4+ T cells play a critical role in co-ordinating 
tumour rejection (174). The data presented in chapters 3 and 4 demonstrate that 
SCLC cells can induce expansion of Treg cells to suppress CD4+ T cell 
proliferation in vitro.  Therefore, future studies should assess the presence of 
CD4+ T cells within the tumour microenvironment that may correlate accurately 
with improved patient survival. The data in chapter 6 indicate that FoxP3+ cell 
number has no prognostic effect to predict patient survival, except when 
considered as a proportion of CD45+ cell numbers. In comparison, studies in 
other cancers demonstrate that the effect of FoxP3+ cells on patient survival is 
controversial. I believe that FoxP3+ cell infiltration as a prognostic marker may 
be tumour-dependent and it may not be accurately used in SCLC. TILs including 
CD8+ T cytotoxic cells, and TAMs including M1 and M2 macrophages, have 
been reported to predict prognosis in other cancers with various results. 
However, the relationship between these immune cell infiltrates and prognosis 
has not been examined extensively in SCLC.  Future experiments may aim to 
collect more SCLC biopsies to identify the number and distribution of these cells 
within the tumour microenvironment, and correlate with patient survival and 
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tumour stage. These investigations would provide in vivo data to correlate with 
the observations from in vitro studies, and validate further study of potential 
targets for anti-cancer therapy.  
 
7.7 Overall model arising from this work and implications for future 
studies.  
 
In this thesis two cell-mediated mechanisms by which SCLC cells may suppress 
immune responses have been identified. Firstly, SCLC cells secrete IL-15 to 
induce CD4+ T cells to adopt a functional Treg phenotype, and patient survival 
correlates negatively with proportion of these cells (CD3+FoxP3+) in tumour 
infiltrate (Fig. 7). However, IL-15 may be an important factor secreted by SCLC 
cells to mediate immunosuppression though not the only such factor. Future 
studies should identify the other immunosuppressive factors. In addition, the 
suppressive mechanism by which these iTreg cells function is independent of IL-
10 and TGF-β. Future experiments may therefore usefully investigate the 
mechanisms by which SCLC cell-induced Treg cells suppress CD4+ T cell 
proliferation. The second mechanism is that SCLC cells can secrete BLPs to 
induce macrophage populations polarized to an alternatively activated M2-like 
phenotype (Fig. 7). Future experiments may usefully investigate their effects on 
proliferation of CD4+ T cells and induction of Treg cells. Moreover, the 
populations of M1- and M2-like macrophages in SCLC tumour infiltrates and 
their effects on patient survival may be determined in future studies.  
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Figure 7: Model scheme of immune suppressive effects of SCLC cells. The immune suppressive 
effects of SCLC cells on CD4+ T cells and macrophages.  1) SCLC cells produce IL-15 to induce 
CD4+ T cells to adopt CD4+CD25+CD127lowHelios-FoxP3+ Treg cells upon activation. The 
induction of Tregs is associated with increased IL-10 release. These iTreg cells can suppress 
effector CD4+ T cell proliferation independent of IL-10 or TGF-β. Analysis of tumour biopsy 
samples demonstrates that the proportion of these FoxP3+ cells in tumour infiltrate negatively 
correlates with patient survival in SCLC. Future studies should identify the other 
immunosuppressive factors and suppressive mechanism of iTreg cells.  2) SCLC cells produce 
BLPs to induce macrophage populations polarized to an alternatively activated M2-like 
phenotype. The polarization is associated with increased expression of CD163 and CD206, and 
decreased expression of CD16 and CD86. IL-10 production is increased and TNF-α/IL-6 
production is reduced. Future experiments may investigate their effects on proliferation of CD4+ 
T cells and induction of Treg cells. The populations of M1- and M2-like macrophages in SCLC 
tumour infiltrates and their effects on patient survival may be determined in future studies. 
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